FILE 'HOME' ENTERED AT 14:29:19 ON 13 NOV 2003

=> file medicine bioscience
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 1.47 1.47

FILE 'ADISCTI' ENTERED AT 14:33:16 ON 13 NOV 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 14:33:16 ON 13 NOV 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 14:33:16 ON 13 NOV 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'BIOSIS' ENTERED AT 14:33:16 ON 13 NOV 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHNO' ENTERED AT 14:33:16 ON 13 NOV 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CANCERLIT' ENTERED AT 14:33:16 ON 13 NOV 2003

FILE 'CAPLUS' ENTERED AT 14:33:16 ON 13 NOV 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEN' ENTERED AT 14:33:16 ON 13 NOV 2003
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'DISSABS' ENTERED AT 14:33:16 ON 13 NOV 2003
COPYRIGHT (C) 2003 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 14:33:16 ON 13 NOV 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 14:33:16 ON 13 NOV 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGLAUNCH' ENTERED AT 14:33:16 ON 13 NOV 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGMONOG2' ENTERED AT 14:33:16 ON 13 NOV 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGNL' ENTERED AT 14:33:16 ON 13 NOV 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 14:33:16 ON 13 NOV 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'EMBAL' ENTERED AT 14:33:16 ON 13 NOV 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 14:33:16 ON 13 NOV 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 14:33:16 ON 13 NOV 2003

FILE 'IFIPAT' ENTERED AT 14:33:16 ON 13 NOV 2003

FILE 'IPA' ENTERED AT 14:33:16 ON 13 NOV 2003

FILE 'JICST-EPLUS' ENTERED AT 14:33:16 ON 13 NOV 2003

FILE 'KOSMET' ENTERED AT 14:33:16 ON 13 NOV 2003

FILE 'LIFESCI' ENTERED AT 14:33:16 ON 13 NOV 2003

FILE 'MEDICONF' ENTERED AT 14:33:16 ON 13 NOV 2003

FILE 'MEDLINE' ENTERED AT 14:33:16 ON 13 NOV 2003

FILE 'NAPRALERT' ENTERED AT 14:33:16 ON 13 NOV 2003

FILE 'NLDB' ENTERED AT 14:33:16 ON 13 NOV 2003

FILE 'NUTRACEUT' ENTERED AT 14:33:16 ON 13 NOV 2003

FILE 'PASCAL' ENTERED AT 14:33:16 ON 13 NOV 2003

FILE 'PCTGEN' ENTERED AT 14:33:16 ON 13 NOV 2003

FILE 'PHARMAML' ENTERED AT 14:33:16 ON 13 NOV 2003

FILE 'PHIC' ENTERED AT 14:33:16 ON 13 NOV 2003

FILE 'PHIN' ENTERED AT 14:33:16 ON 13 NOV 2003

FILE 'SCISEARCH' ENTERED AT 14:33:16 ON 13 NOV 2003

FILE 'TOXCENTER' ENTERED AT 14:33:16 ON 13 NOV 2003

FILE 'USPATFULL' ENTERED AT 14:33:16 ON 13 NOV 2003

FILE 'USPAT2' ENTERED AT 14:33:16 ON 13 NOV 2003

FILE 'AGRICOLA' ENTERED AT 14:33:16 ON 13 NOV 2003

FILE 'ANABSTR' ENTERED AT 14:33:16 ON 13 NOV 2003
COPYRIGHT (c) 2003 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'AQUASCI' ENTERED AT 14:33:16 ON 13 NOV 2003
COPYRIGHT 2003 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 14:33:16 ON 13 NOV 2003
COPYRIGHT (C) 2003 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOCOMMERCE' ENTERED AT 14:33:16 ON 13 NOV 2003
COPYRIGHT (C) 2003 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 14:33:16 ON 13 NOV 2003
COPYRIGHT (C) 2003 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'CABA' ENTERED AT 14:33:16 ON 13 NOV 2003
COPYRIGHT (C) 2003 CAB INTERNATIONAL (CABI)

FILE 'CEABA-VTB' ENTERED AT 14:33:16 ON 13 NOV 2003
COPYRIGHT (c) 2003 DECHEMA eV

FILE 'CIN' ENTERED AT 14:33:16 ON 13 NOV 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 14:33:16 ON 13 NOV 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 14:33:16 ON 13 NOV 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 14:33:16 ON 13 NOV 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGUPDATES' ENTERED AT 14:33:16 ON 13 NOV 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'FEDRIP' ENTERED AT 14:33:16 ON 13 NOV 2003

FILE 'FOMAD' ENTERED AT 14:33:16 ON 13 NOV 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 14:33:16 ON 13 NOV 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 14:33:16 ON 13 NOV 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 14:33:16 ON 13 NOV 2003
COPYRIGHT (C) 2003 International Food Information Service

FILE 'GENBANK' ENTERED AT 14:33:16 ON 13 NOV 2003

FILE 'HEALSAFE' ENTERED AT 14:33:16 ON 13 NOV 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'NIOSHTIC' ENTERED AT 14:33:16 ON 13 NOV 2003
COPYRIGHT (C) 2003 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 14:33:16 ON 13 NOV 2003

FILE 'OCEAN' ENTERED AT 14:33:16 ON 13 NOV 2003

FILE 'PHAR' ENTERED AT 14:33:16 ON 13 NOV 2003

FILE 'PROMT' ENTERED AT 14:33:16 ON 13 NOV 2003

FILE 'RDISCLOSURE' ENTERED AT 14:33:16 ON 13 NOV 2003

FILE 'SYNTHLINE' ENTERED AT 14:33:16 ON 13 NOV 2003

FILE 'VETB' ENTERED AT 14:33:16 ON 13 NOV 2003

FILE 'VETU' ENTERED AT 14:33:16 ON 13 NOV 2003

FILE 'WPIDS' ENTERED AT 14:33:16 ON 13 NOV 2003

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s amylin (s)(bone# or chondrocyte# or cartilage or tibia? or epiphysea?) and treat?

L1	2	FILE ADISCTI
L2	0	FILE ADISINSIGHT
L3	0	FILE ADISNEWS
L4	12	FILE BIOSIS
L5	4	FILE BIOTECHNO
L6	0	FILE CANCERLIT
L7	21	FILE CAPLUS
L8	0	FILE CEN
L9	2	FILE DISSABS
L10	7	FILE DGENE
L11	0	FILE DRUGB
L12	0	FILE DRUGLAUNCH
L13	0	FILE DRUGMONOG2
L14	3	FILE DRUGNL
L15	5	FILE DRUGU
L16	0	FILE EMBAL
L17	11	FILE EMBASE
L18	7	FILE ESBIOBASE
L19	11	FILE IFIPAT
L20	0	FILE IPA
L21	0	FILE JICST-EPLUS
L22	0	FILE KOSMET
L23	5	FILE LIFESCI
L24	0	FILE MEDICONF
L25	9	FILE MEDLINE
L26	0	FILE NAPRALERT
L27	8	FILE NLDB
L28	0	FILE NUTRACEUT
L29	5	FILE PASCAL
L30	0	FILE PCTGEN
L31	1	FILE PHARMAML
L32	0	FILE PHIC
L33	6	FILE PHIN

```
L34          11 FILE SCISEARCH
L35           0 FILE TOXCENTER
L36          89 FILE USPATFULL
L37          11 FILE USPAT2
L38           0 FILE AGRICOLA
L39           0 FILE ANABSTR
L40           0 FILE AQUASCI
L41           0 FILE BIOBUSINESS
L42           1 FILE BIOCOMMERCE
L43           0 FILE BIOTECHDS
L44           2 FILE CABA
L45           0 FILE CEABA-VTB
L46           1 FILE CIN
L47           0 FILE CONFSCI
L48           0 FILE CROPB
L49           0 FILE CROPU
L50           2 FILE DRUGUPDATES
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'AMYLIN (S)(BONE#'
L51           0 FILE FEDRIP
L52           0 FILE FOMAD
L53           0 FILE FOREGE
L54           0 FILE FROSTI
L55           0 FILE FSTA
L56           0 FILE GENBANK
L57           0 FILE HEALSAFE
L58           0 FILE NIOSHTIC
L59           0 FILE NTIS
L60           0 FILE OCEAN
L61           0 FILE PHAR
L62           6 FILE PROMT
L63           0 FILE RDISCLOSURE
L64           0 FILE SYNTHLINE
L65           0 FILE VETB
L66           0 FILE VETU
L67          15 FILE WPIDS

TOTAL FOR ALL FILES
L68         257 AMYLIN (S)(BONE# OR CHONDROCYTE# OR CARTILAGE OR TIBIA? OR EPIPH
                YSEA?) AND TREAT?

=> s l68 and cartilage (w) (proliferat/ or grow/)
'PROLIFERAT/ ' IS NOT A VALID FIELD CODE
For a list of field codes for the current file, enter "HELP SFIELDS"
at an arrow prompt (=>).

=> s L68 and cartilage (w) (proliferat/ or grow?)
'PROLIFERAT/ ' IS NOT A VALID FIELD CODE
For a list of field codes for the current file, enter "HELP SFIELDS"
at an arrow prompt (=>).

=> s L68 cartilage (w) (proliferat? or grow?)
MISSING OPERATOR L68 CARTILAGE
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s L6 and cartilage (w) (proliferat? or grow?)
L69           0 FILE ADISCTI
L70           0 FILE ADISINSIGHT
L71           0 FILE ADISNEWS
L72           0 FILE BIOSIS
L73           0 FILE BIOTECHNO
<------User Break------>

SEARCH ENDED BY USER
```

SEARCH ENDED BY USER

=> s L68 and cartilage (w) (proliferat? or grow?)\
MISSING OPERATOR GROW?)\
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s L68 and cartilage (w) (proliferat? or grow?)
L74 0 FILE ADISCTI
L75 0 FILE ADISINSIGHT
L76 0 FILE ADISNEWS
L77 0 FILE BIOSIS
L78 0 FILE BIOTECHNO
L79 0 FILE CANCERLIT
L80 1 FILE CAPLUS
L81 0 FILE CEN
L82 0 FILE DISSABS
L83 1 FILE DGENE
L84 0 FILE DRUGB
L85 0 FILE DRUGLAUNCH
L86 0 FILE DRUGMONOG2
L87 0 FILE DRUGNL
L88 0 FILE DRUGU
L89 0 FILE EMBAL
L90 0 FILE EMBASE
L91 0 FILE ESBIOBASE
L92 0 FILE IFIPAT
L93 0 FILE IPA
L94 0 FILE JICST-EPLUS
L95 0 FILE KOSMET
L96 0 FILE LIFESCI
L97 0 FILE MEDICONF
L98 0 FILE MEDLINE
L99 0 FILE NAPRALERT
L100 0 FILE NLDB
L101 0 FILE NUTRACEUT
L102 0 FILE PASCAL
L103 0 FILE PCTGEN
L104 0 FILE PHARMAML
L105 0 FILE PHIC
L106 0 FILE PHIN
L107 0 FILE SCISEARCH
L108 0 FILE TOXCENTER
L109 0 FILE USPATFULL
L110 0 FILE USPAT2
L111 0 FILE AGRICOLA
L112 0 FILE ANABSTR
L113 0 FILE AQUASCI
L114 0 FILE BIOBUSINESS
L115 0 FILE BIOCOMMERCE
L116 0 FILE BIOTECHDS
L117 0 FILE CABA
L118 0 FILE CEABA-VTB
L119 0 FILE CIN
L120 0 FILE CONFSCI
L121 0 FILE CROPB
L122 0 FILE CROPU
L123 0 FILE DRUGUPDATES
L124 0 FILE FEDRIP
L125 0 FILE FOMAD
L126 0 FILE FOREGE
L127 0 FILE FROSTI
L128 0 FILE FSTA
L129 0 FILE GENBANK
L130 0 FILE HEALSAFE

```
L131          0 FILE NIOSHTIC
L132          0 FILE NTIS
L133          0 FILE OCEAN
L134          0 FILE PHAR
L135          0 FILE PROMT
L136          0 FILE RDISCLOSURE
L137          0 FILE SYNTHLINE
L138          0 FILE VETB
L139          0 FILE VETU
L140          1 FILE WPIDS

TOTAL FOR ALL FILES
L141          3 L68 AND CARTILAGE (W) (PROLIFERAT? OR GROW?)

=> s (cartilage or chondrocyte) (s) (proliferat? or grow?)
L142         67 FILE ADISCTI
L143         24 FILE ADISINSIGHT
L144         21 FILE ADISNEWS
L145       5724 FILE BIOSIS
L146       2346 FILE BIOTECHNO
L147       2137 FILE CANCERLIT
L148       5315 FILE CAPLUS
L149         10 FILE CEN
L150        324 FILE DISSABS
<------User Break------>

SEARCH ENDED BY USER
SEARCH ENDED BY USER

=> s l68 and cartilage (w) (proliferat? or grow?)
L151          0 FILE ADISCTI
L152          0 FILE ADISINSIGHT
L153          0 FILE ADISNEWS
L154          0 FILE BIOSIS
L155          0 FILE BIOTECHNO
L156          0 FILE CANCERLIT
L157          1 FILE CAPLUS
L158          0 FILE CEN
L159          0 FILE DISSABS
<------User Break------>

SEARCH ENDED BY USER

=> s l68 and (cartilage or chondrocyte) (s) (proliferat? or grow?)
L160          0 FILE ADISCTI
L161          0 FILE ADISINSIGHT
L162          0 FILE ADISNEWS
L163          1 FILE BIOSIS
L164          0 FILE BIOTECHNO
L165          0 FILE CANCERLIT
L166          4 FILE CAPLUS
L167          0 FILE CEN
L168          1 FILE DISSABS
L169          1 FILE DGENE
L170          0 FILE DRUGB
L171          0 FILE DRUGLAUNCH
L172          0 FILE DRUGMONOG2
L173          0 FILE DRUGNL
L174          0 FILE DRUGU
L175          0 FILE EMBAL
L176          0 FILE EMBASE
L177          0 FILE ESBIOBASE
L178          2 FILE IFIPAT
L179          0 FILE IPA
L180          0 FILE JICST-EPLUS
```

```
L181          0 FILE KOSMET
L182          1 FILE LIFESCI
L183          0 FILE MEDICONF
L184          0 FILE MEDLINE
L185          0 FILE NAPRALERT
L186          1 FILE NLDB
L187          0 FILE NUTRACEUT
L188          0 FILE PASCAL
L189          0 FILE PCTGEN
L190          0 FILE PHARMAML
L191          0 FILE PHIC
L192          1 FILE PHIN
L193          0 FILE SCISEARCH
L194          0 FILE TOXCENTER
L195         11 FILE USPATFULL
L196          0 FILE USPAT2
L197          0 FILE AGRICOLA
L198          0 FILE ANABSTR
L199          0 FILE AQUASCI
L200          0 FILE BIOBUSINESS
L201          0 FILE BIOCOMMERCE
L202          0 FILE BIOTECHDS
L203          0 FILE CABA
L204          0 FILE CEABA-VTB
L205          0 FILE CIN
L206          0 FILE CONFSCI
L207          0 FILE CROPB
L208          0 FILE CROPU
L209          0 FILE DRUGUPDATES
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'NDROCYTE) (S) '
L210          0 FILE FEDRIP
L211          0 FILE FOMAD
L212          0 FILE FOREGE
L213          0 FILE FROSTI
L214          0 FILE FSTA
L215          0 FILE GENBANK
L216          0 FILE HEALSAFE
L217          0 FILE NIOSHTIC
L218          0 FILE NTIS
L219          0 FILE OCEAN
L220          0 FILE PHAR
L221          0 FILE PROMT
L222          0 FILE RDISCLOSURE
L223          0 FILE SYNTHLINE
L224          0 FILE VETB
L225          0 FILE VETU
L226          1 FILE WPIDS

TOTAL FOR ALL FILES
L227         24 L68 AND (CARTILAGE OR CHONDROCYTE) (S) (PROLIFERAT? OR GROW?)

=> dup rem l227
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, DGENE, DRUGLAUNCH,
DRUGMONOG2, KOSMET, MEDICONF, NUTRACEUT, PCTGEN, PHARMAML, BIOCOMMERCE,
DRUGUPDATES, FEDRIP, FOREGE, GENBANK, PHAR, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L227
L228          20 DUP REM L227 (4 DUPLICATES REMOVED)

=> d l228 1-20 ibib abs

L228 ANSWER 1 OF 20  USPATFULL on STN
ACCESSION NUMBER:        2003:282611  USPATFULL
TITLE:                   Human cDNAs and proteins and uses thereof
```

INVENTOR(S): Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PATENT ASSIGNEE(S): GENSET, S.A., Paris, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003198954	A1	20031023
APPLICATION INFO.:	US 2001-1142	A1	20011114 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2001-IB1715	20010806
	US 2001-305456P	20010713 (60)
	US 2001-302277P	20010629 (60)
	US 2001-298698P	20010615 (60)
	US 2001-293574P	20010525 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1, GAINESVILLE, FL, 326066669
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 25681
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the **treatment** of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L228 ANSWER 2 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2003:244219 USPATFULL
TITLE: Human cDNAs and proteins and uses thereof
INVENTOR(S): Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PATENT ASSIGNEE(S): GENSET, S.A., Paris, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003170628	A1	20030911
APPLICATION INFO.:	US 2001-999570	A1	20011114 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2001-IB1715	20010806
	US 2001-305456P	20010713 (60)
	US 2001-302277P	20010629 (60)
	US 2001-298698P	20010615 (60)
	US 2001-293574P	20010525 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1, GAINESVILLE, FL, 326066669
NUMBER OF CLAIMS: 13

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 25549
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the **treatment** of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L228 ANSWER 3 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2003:231986 USPATFULL
TITLE: Human cDNAs and proteins and uses thereof
INVENTOR(S): Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PATENT ASSIGNEE(S): GENSET, S.A., Paris, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003162186	A1	20030828
APPLICATION INFO.:	US 2002-154678	A1	20020522 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-293574P	20010525 (60)
	US 2001-298698P	20010615 (60)
	US 2001-302277P	20010629 (60)
	US 2001-305456P	20010713 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1, GAINESVILLE, FL, 326066669
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 25533
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the **treatment** of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L228 ANSWER 4 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2003:225673 USPATFULL
TITLE: Human cDNAs and proteins and uses thereof
INVENTOR(S): Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PATENT ASSIGNEE(S): GENSET, S.A., Paris, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003157485	A1	20030821
APPLICATION INFO.:	US 2001-992095	A1	20011113 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2001-IB1715	20010806
	US 2001-305456P	20010713 (60)
	US 2001-302277P	20010629 (60)
	US 2001-298698P	20010615 (60)
	US 2001-293574P	20010525 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1, GAINESVILLE, FL, 326066669
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 25484
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the **treatment** of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L228 ANSWER 5 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2003:140406 USPATFULL
TITLE: Human cDNAs and proteins and uses thereof
INVENTOR(S): Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PATENT ASSIGNEE(S): GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003096247	A1	20030522
APPLICATION INFO.:	US 2001-986	A1	20011114 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2001-IB1715	20010806
	US 2001-305456P	20010713 (60)
	US 2001-302277P	20010629 (60)
	US 2001-298698P	20010615 (60)
	US 2001-293574P	20010525 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: John Lucas, Ph.D., J.D., GENSET CORP., 10665 Sorrento Valley Road, San Diego, CA, 92121-1609
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 25656
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the

treatment of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L228 ANSWER 6 OF 20 USPATFULL on STN

ACCESSION NUMBER:	2003:133926 USPATFULL
TITLE:	Human cDNAs and proteins and uses thereof
INVENTOR(S):	Bejanin, Stephane, Paris, FRANCE Tanaka, Hiroaki, Antony, FRANCE
PATENT ASSIGNEE(S):	GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003092011	A1	20030515
APPLICATION INFO.:	US 2001-489	A1	20011114 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2001-IB1715	20010806
	US 2001-305456P	20010713 (60)
	US 2001-302277P	20010629 (60)
	US 2001-298698P	20010615 (60)
	US 2001-293574P	20010525 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	John Lucas, Ph.D., J.D., GENSET CORP., 10665 Sorrento Valley Road, San Diego, CA, 92121-1609
NUMBER OF CLAIMS:	13
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	4 Drawing Page(s)
LINE COUNT:	25607

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the **treatment** of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L228 ANSWER 7 OF 20 USPATFULL on STN

ACCESSION NUMBER:	2003:37603 USPATFULL
TITLE:	Human cDNAs and proteins and uses thereof
INVENTOR(S):	Bejanin, Stephane, Paris, FRANCE Tanaka, Hiroaki, Antony, FRANCE
PATENT ASSIGNEE(S):	GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003027248	A1	20030206
APPLICATION INFO.:	US 2001-924340	A1	20010806 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-305456P	20010713 (60)
	US 2001-302277P	20010629 (60)
	US 2001-298698P	20010615 (60)
	US 2001-293574P	20010525 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GENSET, JOHN LUCAS, PHD, J.D., 10665 SORRENTO VALLEY RD, SAN DIEGO, CA, 92121
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 25650
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the **treatment** of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L228 ANSWER 8 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2003:37516 USPATFULL
TITLE: Human cDNAs and proteins and uses thereof
INVENTOR(S): Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PATENT ASSIGNEE(S): GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003027161	A1	20030206
APPLICATION INFO.:	US 2001-992600	A1	20011113 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2001-IB1715	20010806
	US 2001-305456P	20010713 (60)
	US 2001-302277P	20010629 (60)
	US 2001-298698P	20010615 (60)
	US 2001-293574P	20010525 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: John Lucas, Ph.D., J.D., GENSET CORP., 10665 Sorrento Valley Road, San Diego, CA, 92121-1609
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 25529
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the **treatment** of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L228 ANSWER 9 OF 20 IFIPAT COPYRIGHT 2003 IFI on STN DUPLICATE 1
AN 10096001 IFIPAT;IFIUDB;IFICDB
TITLE: METHODS OF **TREATING** BONE OR CARTILAGE CONDITIONS BY THE ADMINISTRATION OF CREATINE; WOUND HEALING AGENT; GENETIC ENGINEERING
INVENTOR(S): Gerber; Isabel, Pieterlen, CH

Wallimann; Theo, Kindhausen, CH
PATENT ASSIGNEE(S): Unassigned
AGENT: PENNIE & EDMONDS LLP, 1667 K STREET NW, SUITE 1000, WASHINGTON, DC, 20006

	NUMBER	PK	DATE
PATENT INFORMATION:	US 2002039567	A1	20020404
APPLICATION INFORMATION:	US 2001-769404		20010126
FAMILY INFORMATION:	US 2002039567		20020404

DOCUMENT TYPE: Utility
Patent Application - First Publication
FILE SEGMENT: CHEMICAL
APPLICATION
NUMBER OF CLAIMS: 27 5 Figure(s).
DESCRIPTION OF FIGURES:
FIG. 1 is a graph showing Viability (NR) of monolayer osteoblast cell cultures at 1, 2, and 3 weeks in the absence (control) and presence of either 10 mM or 20 mM creatine in the medium;
FIG. 2 is a graph showing metabolic activity (MTT) of monolayer osteoblast cell cultures at 1, 2, and 3 weeks in the absence (control) and presence of either 10 mM or 20 mM creatine in the medium;
FIG. 3 is a graph showing mineralization of monolayer osteoblast cell culture at 2 and 3 weeks in the absence (control) and presence of either 10 mM or 20 mM creatine in the medium;
FIG. 4 is a graph showing mineralization of micromass osteoblast cell culture at 2 and 3 weeks in the absence (control) and presence of either 10 mM or 20 mM creatine in the medium; and
FIG. 5 is a graph showing embryonic rat femora wet weight after 3 weeks in organ culture, with and without 10 mM or 20 mM creatine.

AB The method, composition, and use of the composition for healing defects in bone or cartilage tissue in animals and humans caused by trauma or surgery is disclosed. The method includes administration of creatine compounds including analogues or pharmaceutically acceptable salts thereof. **Treatment** in accordance with the method speeds-up time for and improves the process of healing of defects in bone or cartilage tissue in animals and humans caused by trauma or surgery including acceptance and bonding of artificial implants. The **treatment** with creatine compounds can be therapeutic for diseased patients, preventive for healthy people, as well as geriatric for elderly people.

CLMN 27 5 Figure(s).
FIG. 1 is a graph showing Viability (NR) of monolayer osteoblast cell cultures at 1, 2, and 3 weeks in the absence (control) and presence of either 10 mM or 20 mM creatine in the medium;
FIG. 2 is a graph showing metabolic activity (MTT) of monolayer osteoblast cell cultures at 1, 2, and 3 weeks in the absence (control) and presence of either 10 mM or 20 mM creatine in the medium;
FIG. 3 is a graph showing mineralization of monolayer osteoblast cell culture at 2 and 3 weeks in the absence (control) and presence of either 10 mM or 20 mM creatine in the medium;
FIG. 4 is a graph showing mineralization of micromass osteoblast cell culture at 2 and 3 weeks in the absence (control) and presence of either 10 mM or 20 mM creatine in the medium; and
FIG. 5 is a graph showing embryonic rat femora wet weight after 3 weeks in organ culture, with and without 10 mM or 20 mM creatine.

L228 ANSWER 10 OF 20 IFIPAT COPYRIGHT 2003 IFI on STN
AN 10112008 IFIPAT;IFIUDB;IFICDB
TITLE: FUNCTIONAL ROLE OF ADRENOMEDULLIN (AM) AND THE GENE-RELATED PRODUCT (PAMP) IN HUMAN PATHOLOGY AND PHYSIOLOGY; PEPTIDE FOR USE IN THE DIAGNOSIS, **TREATMENT** AND PREVENTION OF INFECTIONS, CANCER, DIABETES AND SKIN DISORDERS; WOUNG HEALING AGENTS, ANTICARCINOGENEIC AGENTS
INVENTOR(S): Cuttitta; Frank, Adamstown, MD, US

Gray; Karen, Gaithersburg, MD, US
Hook; William, Wheaton, MD, US
Macri; Charles, Kensington, MD, US
Martinez; Alfredo, McLean, VA, US
Miller; Mae Jean, Monrovia, MD, US
Unsworth; Edward J., Kensington, MD, US
Walsh; Thomas, Bethesda, MD, US
PATENT ASSIGNEE(S): Unassigned
AGENT: MORGAN & FINNEGAN, L.L.P., 345 Park Avenue, New York, NY, 10154-0053, US

	NUMBER	PK	DATE
PATENT INFORMATION:	US 2002055615	A1	20020509
APPLICATION INFORMATION:	US 2001-931700		20010816

	APPLN. NUMBER	DATE	GRANTED PATENT NO. OR STATUS
DIVISION OF:	US 1998-11922	19980217	6320022

	NUMBER	DATE	
PRIORITY APPLN. INFO.:	WO 1996-US13286	19960816	
	US 1995-2514P	19950818	(Provisional)
	US 1995-2936P	19950830	(Provisional)
	US 1996-13172P	19960312	(Provisional)
FAMILY INFORMATION:	US 2002055615	20020509	
	US 6320022		

DOCUMENT TYPE: Utility
Patent Application - First Publication
FILE SEGMENT: CHEMICAL
APPLICATION
NUMBER OF CLAIMS: 16 27 Figure(s).

DESCRIPTION OF FIGURES:

FIG. 1: FIG. 1 sets forth a schematic drawing showing the structures of the human AM gene, mRNA, and preprohormone containing the two biologically active molecules, AM and pro-AM peptide (PAMP). The positions of the oligonucleotides and peptides synthesized are shown. Numbers in the gene and mRNA indicate base pairs from the initiation codon. Numbers in the protein correspond to amino acids. Data are modified from the report of Ishimitsu, et al., Biochem Biophys Res Commun 203:631639 (1994).

FIG. 2: FIG. 2 sets forth a titration curve for rabbit anti-PO72 immunogen (bleed 2343) binding to solid phase test peptides. A measurable antibody interaction was observed in AM, PO72, PO71, NPY, and CGRP. All other target peptides (PO70, gastrinreleasing peptide, glucagon-like peptide 1, vasoactive intestinal peptide, arginine vasopressin, GRF, cholecystokinin, gastrin, oxytocin, calcitonin, alpha MSH, and BSA) showed negligible binding.

FIG. 3: Detection of AM-like immunoreactive species in the whole cell lysate of a human lung carcinoid cell line, NCI-H720. The right lane contains 2 ng synthetic PO72 (molecular weight, 3576) . The specificity of detection is demonstrated by antigen absorption of anti-PO72 antiserum (right panel).

FIGS. 4A, 4B, 4C, and 4D: FIGS. 4A-4D set forth a cross-section (magnification x 450) of a bronchiolus showing immunoreactivity to the anti-AM antiserum in the epithelium (FIG. 4A) and labeling of the AM mRNA after in situ RT-PCR (FIG. 4C). Absorption controls (FIG. 4B) and omission of the RT (FIG. 4D) confirmed the specificity of the staining.

FIGS. 5A, 5B, 5C, and 5D: FIGS. 5A-5D set forth photographs of a section through the adventitia layer of a bronchus showing a small nervous ganglion where the perykaria of the neurons and some nerves are immunostained (FIG. 5A), whereas a serial section **treated** with preabsorbed antiserum was negative (FIG. 5B). (Magnification x 450). Another ganglion appears labeled, at lower magnification (x 120), after application of the in situ RT-PCR technique (FIG. 5C). Arrows point to blood vessels whose endothelial layers are clearly positive. Omission of primers in the PCR mixture gave negative staining (FIG.

5D).
FIGS. 6A and 6B: FIG. 6A and 6B set forth photographs of the detail of ***chondrocytes*** immunostained with anti-AM (FIG. 6A) and with the antiserum preabsorbed with PO72 (FIG. 6B). (Magnification x 700).
FIG. 7A and 7B: FIGS. 7A and 7B set forth photographs of alveolar macrophages labeled for AM mRNA after in situ RT-PCR (FIG. 7A) and negative control without reverse transcriptase (FIG. 7B). (Magnification x 450).
FIG. 8: Characterization of AM by RT-PCR in mRNA from normal tissues and pulmonary tumor cell lines. The PCR products had the proper size (410 bp) when visualized with UV light (lower panel), and they hybridized with the specific probe after Southern blot (upper panel). H146 and H345 are small cell carcinomas, H676 is an adenocarcinoma, H720 is a carcinoid, and H820 is a bronchioalveolar carcinoma. H146 was the only cell line that tested negative for AM.
FIGS. 9A and 9B: FIGS. 9A and 9B set forth photographs of cell line H820 (bronchioalveolar carcinoma) showing a cytoplasmic distribution of AM mRNA, as revealed by in situ RT-PCR (FIG. 9A) , and a serial section demonstrating that the staining disappears when the reverse transcription step is omitted (FIG. 9B). (Magnification x 550)
FIGS. 10A and 10B: FIGS. 10A and 10B set forth photographs of serial sections of an adenocarcinoma showing AM mRNA in the tumor cells by in situ RT-PCR (FIG. 10A) and immunocytochemistry (FIG. 10B). (Magnification x 550)
FIG. 11: FIG. 11 sets forth a chart indicating histamine release from rat mast cells.
FIGS. 12A and 12B: FIGS. 12A and 12B indicate the effect of antiAM MoAb on the ***growth*** of human tumor cell lines.
FIG. 13: FIG. 13 sets forth a characterization of the monoclonal antibody MoAb-G6 showing binding to AM (composite-function) and to two PO72 molecules: an in-house peptide (circle-solid) and a Peninsula peptide product (*). All other peptides: PO70, GRP, GLP1, VIP, AVP, GRF, CCK, **amylin**, gastrin, oxytocin, AMSH, pancreatic polypeptide, peptide YY, Taa-HoTH (Tabanus atratus Hypotrehalosemic Hormone), and BSA, showed negligible binding. Solid-phase assays were conducted using previously described methods (Cuttitta, et al., Nature 316, 823 (1985)).
FIGS. 14A, 14B, 14C and 14D: FIGS. 14A and 14B show a representative sample of human tumor cell lines (H157, H720, MCF-7, OVCAR-3, SNUC-1) and normal human tissues (brain, lung, heart, adrenal) screened for AM mRNA and its translated protein. FIG. 14A is a Southern blot analysis and FIG. 14B is the ethidium bromide 1% agarose gel which demonstrates the predicted 410 bp product for AM mRNA as evaluated by RT-PCR analysis. FIG. 14C sets forth a Western blot analysis showing immunoreactive species of 18, 14, and 6 kDa when using a rabbit antiserum to AM.
FIGS. 15A, 15B and 15C: FIGS. 15A-15C set forth an HPLC profile, solid phase plate assay and Western blot analysis of H720 conditioned medium (CM). FIG. 15A illustrates the fractionation of 5 L of H720 CM compared with the elution time of synthetic AM at 89.4 min (arrow).
FIGS. 16A, 16B, 16C and 16D: A representative human tumor cell line, MCF-7, was used to show the **growth** effects, cAMP activity and receptor binding by AM under serumfree, hormone-free conditions. FIG. 16A shows the inhibitory effects of MoAb-G6 (circle-solid) compared with no effect from its mouse myeloma isotypic control, IgAK (Sigma) (composite-function). FIG. 16B shows that the effects of MoAb-G6 were overcome by the addition of synthetic AM (composite-function) compared with the addition of AM alone (circle-solid). FIG. 16C indicates that cyclic AMP is activated with the addition of synthetic AM. FIG. 16D shows that specific receptor binding is higher for AM (composite-function) than for PAMP (*) or PO72 (circle-solid). MTT (Carney, et al., Proc. Natl. Acad Sci. U.S.A. 79, 3185 (1981)) and receptor binding/cAMP assay techniques (T. W. Moody, et al., Proc. Natl. Acad. Sci U.S.A. 90, 4345 (1993)) are described elsewhere.
FIGS. 17A-17H: FIGS. 17A-17H set forth the distribution of adrenomedullin (AM) in the pancreas as shown by immunocytochemistry.
FIGS. 18A and 18B: Effects of AM and MoAb-G6 (alpha-AM) on the release of insulin from rat isolated islets. (FIG. 18A) Increasing concentration of AM reduces insulin secretion in the presence (composite-function) or absence (circle-solid) of MoAb-G6 antibody. Note dramatic increase in insulin secretion

mediated by the antibody. (FIG. 18B)
FIGS. 19A and 19B: FIG. 19A shows a Southern blot for AM in six cell lines expressing insulin and in human adrenal and pancreas mRNA. FIG. 19B shows the same gel as seen by UV before transfer.
FIGS. 20A and 20B: Glucose tolerance tests were performed on Sprague-Dawley rats (250 to 300 g) in the presence (compositefunction) or absence (circle-solid) of AM.
FIGS. 21A-21I: FIG. 21 sets forth in panels A-I the localization of AM mRNA and immunoreactivity in various organs of different species. Panel A shows mRNA for AM detected by in situ RT-PCR in the epithelial cells of the rat trachea. Panel B sets forth guinea pig trachea displaying a strong immunoreactivity to the AM antibody, specially in the apical region. Panel C depicts a Xenopus respiratory tract, with intense immunostaining in the supranuclear region. Panel D shows Xenopus integument with AM immunoreactivity concentrated in the unicellular glands of the epidermis (two of which appear in this figure). The dark spot to the left is a chromatophore. Panel E shows skin of a 16-day old mouse embryo. An intense immunoreactivity to AM is observed in the epidermis and in the subjacent developing muscles. Panel F sets forth a hamster uterus showing immunostaining for AM in both the lining epithelium and the glands. Panel G shows a small salivary gland found in the hamster tongue. Discrete secretory cells store the AM-like material. Panel R shows rat duodenum with intensely immunostained Brunner's glands. Panel I shows a section of cat colon containing an AM-positive endocrine cell.
FIG. 22; FIG. 22 indicates the effect of AM and PAMP on the inhibition of ***growth*** of E. coli. AM demonstrated higher **growth** inhibitory activity than albumin (Alb) (negative control) (*, p=0.03), PO70 (pilcrow, p=0.04), PO71 (pilcrow, p=0.006), and PO72 (pilcrow, p=0.03). Magainin (M) exerted greater inhibitory activity against E. coli than did AM (* pilcrow section dagger-relation, p=0.03) and PAMP (section daggerrelation, p=0.009). Data were compiled from 14 experiments.
FIGS. 23A and 23B: FIGS. 23A and 23B set forth the antimicrobial activity of AM and PAMP.
FIG. 24: FIG. 24 indicates the effect of AM on the germination of C. albicans.
FIG. 25: FIG. 25 sets forth the distribution of amphipathic regions for AM and PAMP as calculated for a-helix/b-sheet angle parameters (Eisenberg), and the helical wheel projection display for AM and PAMP (DNASTAR).
FIGS. 26A-26D: FIG. 26 sets forth a representative sample of human tumor cell lines and normal human tissues screened for AM and AM-R. Southern blot analysis demonstrates the predicted 410 bp product for AM (A) and a 471 bp product for AM-R mRNA (B) after RT-PCR amplification. (C) Western blot analysis of cell extracts shows immunoreactive species of 18, 14, and 6 kDa when using a rabbit antiserum to AM. In addition, there is a 22 kDa immunoreactive entity that may be attributed to posttranslational processing. (D) The absorption control was negative.

DESCRIPTION OF FIGURES:

FIGS. 27A-27D: FIG. 27 sets forth the iumunohistochemical and in situ RT-PCR analysis of human cancer cell lines for AM. (A) Immunohistochemical analysis for AM in SCLC H774 and (B) ovarian carcinoma cell line NIH: Ovcar-3. Note the peripheral distribution of AM immunoreactivity in H774 colonies. (C) In situ RT-PCR for AM mRNA in carcinoid cell line H720 and (D) negative control in a serial section where primers were substituted by water in the PCR mixture.!

AB The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for Tpeptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present invention additionally provides for methods of diagnosis, **treatment** and prevention of disease utilizing compositions comprising the AM peptides and antibodies of the present invention. The methods of the present invention also provide for experimental models for use in identifying the role of AM in pancreatic physiology. The methods pertaining to rat isolated islets have shown that AM inhibits insulin secretion in a dose-dependent manner. The monoclonal antibody MoAb-G6, which neutralizes AM bioactivity, was shown by the methods of the present invention to increase insulin release fivefold, an effect that was

reversed by the addition of synthetic AM.

CLMN 16 27 Figure(s).

FIG. 1: FIG. 1 sets forth a schematic drawing showing the structures of the human AM gene, mRNA, and preprohormone containing the two biologically active molecules, AM and pro-AM peptide (PAMP). The positions of the oligonucleotides and peptides synthesized are shown. Numbers in the gene and mRNA indicate base pairs from the initiation codon. Numbers in the protein correspond to amino acids. Data are modified from the report of Ishimitsu, et al., Biochem Biophys Res Commun 203:631639 (1994).

FIG. 2: FIG. 2 sets forth a titration curve for rabbit anti-PO72 immunogen (bleed 2343) binding to solid phase test peptides. A measurable antibody interaction was observed in AM, PO72, PO71, NPY, and CGRP. All other target peptides (PO70, gastrinreleasing peptide, glucagon-like peptide 1, vasoactive intestinal peptide, arginine vasopressin, GRF, cholecystokinin, gastrin, oxytocin, calcitonin, alpha MSH, and BSA) showed negligible binding.

FIG. 3: Detection of AM-like immunoreactive species in the whole cell lysate of a human lung carcinoid cell line, NCI-H720. The right lane contains 2 ng synthetic PO72 (molecular weight, 3576) . The specificity of detection is demonstrated by antigen absorption of anti-PO72 antiserum (right panel).

FIGS. 4A, 4B, 4C, and 4D: FIGS. 4A-4D set forth a cross-section (magnification x 450) of a bronchiolus showing immunoreactivity to the anti-AM antiserum in the epithelium (FIG. 4A) and labeling of the AM mRNA after in situ RT-PCR (FIG. 4C). Absorption controls (FIG. 4B) and omission of the RT (FIG. 4D) confirmed the specificity of the staining.

FIGS. 5A, 5B, 5C, and 5D: FIGS. 5A-5D set forth photographs of a section through the adventitia layer of a bronchus showing a small nervous ganglion where the perykaria of the neurons and some nerves are immunostained (FIG. 5A), whereas a serial section **treated** with preabsorbed antiserum was negative (FIG. 5B). (Magnification x 450). Another ganglion appears labeled, at lower magnification (x 120), after application of the in situ RT-PCR technique (FIG. 5C). Arrows point to blood vessels whose endothelial layers are clearly positive. Omission of primers in the PCR mixture gave negative staining (FIG. 5D).

FIGS. 6A and 6B: FIG. 6A and 6B set forth photographs of the detail of **chondrocytes** immunostained with anti-AM (FIG. 6A) and with the antiserum preabsorbed with PO72 (FIG. 6B). (Magnification x 700).

FIG. 7A and 7B: FIGS. 7A and 7B set forth photographs of alveolar macrophages labeled for AM mRNA after in situ RT-PCR (FIG. 7A) and negative control without reverse transcriptase (FIG. 7B). (Magnification x 450).

FIG. 8: Characterization of AM by RT-PCR in mRNA from normal tissues and pulmonary tumor cell lines. The PCR products had the proper size (410 bp) when visualized with UV light (lower panel), and they hybridized with the specific probe after Southern blot (upper panel). H146 and H345 are small cell carcinomas, H676 is an adenocarcinoma, H720 is a carcinoid, and H820 is a bronchioalveolar carcinoma. H146 was the only cell line that tested negative for AM.

FIGS. 9A and 9B: FIGS. 9A and 9B set forth photographs of cell line H820 (bronchioalveolar carcinoma) showing a cytoplasmic distribution of AM mRNA, as revealed by in situ RT-PCR (FIG. 9A) , and a serial section demonstrating that the staining disappears when the reverse transcription step is omitted (FIG. 9B). (Magnification x 550)

FIGS. 10A and 10B: FIGS. 10A and 10B set forth photographs of serial sections of an adenocarcinoma showing AM mRNA in the tumor cells by in situ RT-PCR (FIG. 10A) and immunocytochemistry (FIG. 10B). (Magnification x 550)

FIG. 11: FIG. 11 sets forth a chart indicating histamine release from rat mast cells.

FIGS. 12A and 12B: FIGS. 12A and 12B indicate the effect of antiAM MoAb on the **growth** of human tumor cell lines.

FIG. 13: FIG. 13 sets forth a characterization of the monoclonal antibody MoAb-G6 showing binding to AM (composite-function) and to two PO72

molecules: an in-house peptide (circle-solid) and a Peninsula peptide product (*). All other peptides: PO70, GRP, GLP1, VIP, AVP, GRF, CCK, **amylin**, gastrin, oxytocin, AMSH, pancreatic polypeptide, peptide YY, Taa-HoTH (Tabanus atratus Hypotrehalosemic Hormone), and BSA, showed negligible binding. Solid-phase assays were conducted using previously described methods (Cuttitta, et al., Nature 316, 823 (1985)).

FIGS. 14A, 14B, 14C and 14D: FIGS. 14A and 14B show a representative sample of human tumor cell lines (H157, H720, MCF-7, OVCAR-3, SNUC-1) and normal human tissues (brain, lung, heart, adrenal) screened for AM mRNA and its translated protein. FIG. 14A is a Southern blot analysis and FIG. 14B is the ethidium bromide 1% agarose gel which demonstrates the predicted 410 bp product for AM mRNA as evaluated by RT-PCR analysis. FIG. 14C sets forth a Western blot analysis showing immunoreactive species of 18, 14, and 6 kDa when using a rabbit antiserum to AM.

FIGS. 15A, 15B and 15C: FIGS. 15A-15C set forth an HPLC profile, solid phase plate assay and Western blot analysis of H720 conditioned medium (CM). FIG. 15A illustrates the fractionation of 5 L of H720 CM compared with the elution time of synthetic AM at 89.4 min (arrow).

FIGS. 16A, 16B, 16C and 16D: A representative human tumor cell line, MCF-7, was used to show the **growth** effects, cAMP activity and receptor binding by AM under serumfree, hormone-free conditions. FIG. 16A shows the inhibitory effects of MoAb-G6 (circle-solid) compared with no effect from its mouse myeloma isotypic control, IgAK (Sigma) (composite-function). FIG. 16B shows that the effects of MoAb-G6 were overcome by the addition of synthetic AM (composite-function) compared with the addition of AM alone (circle-solid). FIG. 16C indicates that cyclic AMP is activated with the addition of synthetic AM. FIG. 16D shows that specific receptor binding is higher for AM (composite-function) than for PAMP (*) or PO72 (circle-solid). MTT (Carney, et al., Proc. Natl. Acad Sci. U.S.A. 79, 3185 (1981)) and receptor binding/cAMP assay techniques (T. W. Moody, et al., Proc. Natl. Acad. Sci U.S.A. 90, 4345 (1993)) are described elsewhere.

FIGS. 17A-17H: FIGS. 17A-17H set forth the distribution of adrenomedullin (AM) in the pancreas as shown by immunocytochemistry.

FIGS. 18A and 18B: Effects of AM and MoAb-G6 (alpha-AM) on the release of insulin from rat isolated islets. (FIG. 18A) Increasing concentration of AM reduces insulin secretion in the presence (composite-function) or absence (circle-solid) of MoAb-G6 antibody. Note dramatic increase in insulin secretion mediated by the antibody. (FIG. 18B)

FIGS. 19A and 19B: FIG. 19A shows a Southern blot for AM in six cell lines expressing insulin and in human adrenal and pancreas mRNA. FIG. 19B shows the same gel as seen by UV before transfer.

FIGS. 20A and 20B: Glucose tolerance tests were performed on Sprague-Dawley rats (250 to 300 g) in the presence (compositefunction) or absence (circle-solid) of AM.

FIGS. 21A-21I: FIG. 21 sets forth in panels A-I the localization of AM mRNA and immunoreactivity in various organs of different species. Panel A shows mRNA for AM detected by in situ RT-PCR in the epithelial cells of the rat trachea. Panel B sets forth guinea pig trachea displaying a strong immunoreactivity to the AM antibody, specially in the apical region. Panel C depicts a Xenopus respiratory tract, with intense immunostaining in the supranuclear region. Panel D shows Xenopus integument with AM immunoreactivity concentrated in the unicellular glands of the epidermis (two of which appear in this figure). The dark spot to the left is a chromatophore. Panel E shows skin of a 16-day old mouse embryo. An intense immunoreactivity to AM is observed in the epidermis and in the subjacent developing muscles. Panel F sets forth a hamster uterus showing immunostaining for AM in both the lining epithelium and the glands. Panel G shows a small salivary gland found in the hamster tongue. Discrete secretory cells store the AM-like material. Panel R shows rat duodenum with intensely immunostained Brunner's glands. Panel I shows a section of cat colon containing an AM-positive endocrine cell.

FIG. 22; FIG. 22 indicates the effect of AM and PAMP on the inhibition of **growth** of E. coli. AM demonstrated higher **growth**

inhibitory activity than albumin (Alb) (negative control) (*, p=0.03), PO70 (pilcrow, p=0.04), PO71 (pilcrow, p=0.006), and PO72 (pilcrow, p=0.03). Magainin (M) exerted greater inhibitory activity against E. coli than did AM (* pilcrow section dagger-relation, p=0.03) and PAMP (section daggerrelation, p=0.009). Data were compiled from 14 experiments.

FIGS. 23A and 23B: FIGS. 23A and 23B set forth the antimicrobial activity of AM and PAMP.

FIG. 24: FIG. 24 indicates the effect of AM on the germination of C. albicans.

FIG. 25: FIG. 25 sets forth the distribution of amphipathic regions for AM and PAMP as calculated for a-helix/b-sheet angle parameters (Eisenberg), and the helical wheel projection display for AM and PAMP (DNASTAR).

FIGS. 26A-26D: FIG. 26 sets forth a representative sample of human tumor cell lines and normal human tissues screened for AM and AM-R. Southern blot analysis demonstrates the predicted 410 bp product for AM (A) and a 471 bp product for AM-R mRNA (B) after RT-PCR amplification. (C) Western blot analysis of cell extracts shows immunoreactive species of 18, 14, and 6 kDa when using a rabbit antiserum to AM. In addition, there is a 22 kDa immunoreactive entity that may be attributed to posttranslational processing. (D) The absorption control was negative.

FIGS. 27A-27D: FIG. 27 sets forth the iumunohistochemical and in situ RT-PCR analysis of human cancer cell lines for AM. (A) Immunohistochemical analysis for AM in SCLC H774 and (B) ovarian carcinoma cell line NIH: Ovcar-3. Note the peripheral distribution of AM immunoreactivity in H774 colonies. (C) In situ RT-PCR for AM mRNA in carcinoid cell line H720 and (D) negative control in a serial section where primers were substituted by water in the PCR mixture.!

L228 ANSWER 11 OF 20 USPATFULL on STN

ACCESSION NUMBER:	2002:329843 USPATFULL
TITLE:	Extracellular signaling molecules
INVENTOR(S):	Tang, Y. Tom, San Jose, CA, UNITED STATES Yue, Henry, Sunnyvale, CA, UNITED STATES Lal, Preeti, Santa Clara, CA, UNITED STATES Burford, Neil, Durham, CT, UNITED STATES Bandman, Olga, Mountain View, CA, UNITED STATES Baughn, Mariah R., San Leandro, CA, UNITED STATES Azimzai, Yalda, Castro Valley, CA, UNITED STATES Lu, Dyung Aina M., San Jose, CA, UNITED STATES Arvizu, Chandra, Menlo Park, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002187523	A1	20021212
APPLICATION INFO.:	US 2001-965528	A1	20010926 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2000-US13975	20000519
	US 1999-134949P	19990519 (60)
	US 1999-144270P	19990715 (60)
	US 1999-146700P	19990730 (60)
	US 1999-157508P	19991004 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	LEGAL DEPARTMENT, INCYTE GENOMICS, INC., 3160 PORTER DRIVE, PALO ALTO, CA, 94304
NUMBER OF CLAIMS:	107
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	2 Drawing Page(s)
LINE COUNT:	5792

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides human extracellular signaling molecules (EXCS) and polynucleotides which identify and encode EXCS. The invention also provides expression vectors, host cells, antibodies, agonists, and

antagonists. The invention also provides methods for diagnosing, **treating**, or preventing disorders associated with expression of EXCS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L228 ANSWER 12 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2002:152617 USPATFULL
TITLE: Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
INVENTOR(S): Isales, Carlos M., 3413 Woodstone Pl., Augusta, GA, United States 30909
Bollag, Roni J., 231 Watervale Rd., Martinez, GA, United States 30907
Rasmussen, Howard, 820 Barrett La., Augusta, GA, United States 30909

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6410508	B1	20020625
APPLICATION INFO.:	US 1999-414189		19991007 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-103495P	19981008 (60)
	US 1998-103333P	19981007 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Priebe, Scott D.
ASSISTANT EXAMINER: Kaushal, Sumesh
LEGAL REPRESENTATIVE: Rothschild, Esq, Cynthia B., Kilpatrick Stockton LLP
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 1515
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The examples demonstrate that GIP receptor mRNA and protein are present in normal bone and osteoblastic-like cell lines, and that high-affinity receptors for GIP can be demonstrated by .sup.125I GIP binding studies. When applied to osteoblast-like cells (SaOS2), GIP stimulated an increase in cellular cAMP content and in intracellular calcium, with both responses being dose dependent. Moreover, administration of GIP results in elevated expression of collagen type I mRNA as well as an increase in alkaline phosphatase activity. Both of these effects reflect anabolic actions of presumptive osteoblasts. These results provide the first evidence that GIP receptors are present in bone and osteoblastic like cells and that GIP modulates the function of these cells. GIP has anabolic actions on remodeling bone, increasing vertebral bone density in a rat model of osteoporosis. GIP at 10 nM inhibits PTH-induced bone resorption in a fetal long bone assay and stimulates the synthesis of type 1 collagen mRNA. Transgenic mice overexpressing GIP have increased bone density compared to same age controls. GIP or analoges thereof can therefore be used as a therapeutic to inhibit bone resorption and to maintain or increase bone density. GIP antagonists, compounds which block binding to the GIP receptor, can be used to decrease bone density.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L228 ANSWER 13 OF 20 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 2
ACCESSION NUMBER: 2003:58689 BIOSIS
DOCUMENT NUMBER: PREV200300058689
TITLE: Effects of amylin and adrenomedullin on the skeleton.
AUTHOR(S): Cornish, J. [Reprint Author]; Reid, I. R.
CORPORATE SOURCE: Department of Medicine, University of Auckland, Private Bag

92019, Auckland, New Zealand
j.cornish@auckland.ac.nz
SOURCE: Journal of Musculoskeletal and Neuronal Interactions, (September 2001) Vol. 2, No. 1, pp. 15-24. print.
ISSN: 1108-7161 (ISSN print).
DOCUMENT TYPE: Article
General Review; (Literature Review)
LANGUAGE: English
ENTRY DATE: Entered STN: 22 Jan 2003
Last Updated on STN: 22 Jan 2003

AB Amylin and adrenomedullin are related peptides with some homology to both calcitonin and calcitonin gene-related peptide (CGRP). All these peptides have in common a 6-amino acid ring structure at the amino-terminus created by a disulfide bond. In addition, the carboxy-termini are amidated. Both **amylin** and adrenomedullin have recently been found to stimulate the proliferation of osteoblasts in vitro, and to increase indices of **bone** formation in vivo when administered either locally or systemically. Both **amylin** and adrenomedullin have also been found to act on **chondrocytes** (Cornish et al., submitted for publication), stimulating their **proliferation** in culture and increasing **tibial growth** plate thickness when administered systemically to adult mice. Studies of structure-activity relationships have demonstrated that osteotropic effects of amylin and adrenomedullin can be retained in peptide fragments of the molecules. The full-length peptide of amylin has known effects on fuel metabolism, and systemic administration of amylin is also associated with increased fat mass. However, the octapeptide fragment of the molecule, amylin-(1-8), is osteotropic and yet has no activity on fuel metabolism. Similar fragments of adrenomedullin have also been defined, which retain activity on bone but lack the parent peptide's vasodilator properties. Both **amylin** -(1-8) and adrenomedullin-(27-52) act as anabolic agents on **bone** , increasing **bone** strength when administered systemically. Thus, these small peptides, or analogues of it, are potential candidates as anabolic therapies for osteoporosis. Both **amylin** and adrenomedullin may have effects on **bone** metabolism. **Amylin** is secreted following eating and may direct calcium and protein absorbed from the meal into new **bone** synthesis. **Amylin** circulates in high concentrations in obese individuals, and might contribute to the association between **bone** mass and fat mass. Our recent findings demonstrating the co-expression of adrenomedullin and adrenomedullin receptors in ostcoblasts, along with the findings that the peptide and its receptor are easily detectable during rodent embryogenesis, suggest that this peptide is a local regulator of bone growth. Thus, the findings reviewed in this 'paper illustrate that **amylin** and adrenomedullin may be relevant to the normal regulation of **bone** mass and to the design of agents for the **treatment** of osteoporosis.

L228 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2000:98312 CAPLUS
DOCUMENT NUMBER: 132:146657
TITLE: Use of creatine compounds for **treatment** of bone or cartilage cells and tissues
INVENTOR(S): Wallimann, Theo; Gerber, Isabel
PATENT ASSIGNEE(S): Synergen A.-G., Switz.; Ao-Forschungsinstitut Davos
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000006150	A1	20000210	WO 1998-EP4713	19980728

W: CA, JP, US
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

CA 2338712	AA	20000210	CA 1998-2338712	19980728
EP 1100488	A1	20010523	EP 1998-942645	19980728
EP 1100488	B1	20030423		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI

JP 2002521440	T2	20020716	JP 2000-562005	19980728
AT 238049	E	20030515	AT 1998-942645	19980728
US 2002039567	A1	20020404	US 2001-769404	20010126

PRIORITY APPLN. INFO.: WO 1998-EP4713 A 19980728
OTHER SOURCE(S): MARPAT 132:146657

AB The method, compn. and use of the compn. for healing defects in bone or cartilage tissue in animals and humans caused by trauma or surgery is disclosed. The method comprises administration of creatine compds. including analogs or pharmaceutically acceptable salts thereof. **Treatment** in accordance with this method speeds-up time for and improves the process of healing of defects in bone or cartilage tissue in animals and humans caused by trauma or surgery including acceptance and bonding of artificial implants. The **treatment** with creatine compds. can be therapeutic for diseased patients, preventive for healthy people as well as geriatric for elderly people. Creatine stimulated the metabolic activity of rat osteoblasts from the second week onwards. Creatine-**treated** groups also had significantly more mineralization than the control at two weeks.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L228 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 3
ACCESSION NUMBER: 1999:233770 CAPLUS
DOCUMENT NUMBER: 130:247465
TITLE: Stimulation of **chondrocyte proliferation** by **amylin** and adrenomedullin
INVENTOR(S): Reid, Ian Reginald; Cornish, Jillian
PATENT ASSIGNEE(S): Auckland Uniservices Limited, N. Z.
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9916406	A2	19990408	WO 1998-NZ145	19980925
WO 9916406	A3	19990708		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1027027	A2	20000816	EP 1998-946738	19980925

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

JP 2001524454	T2	20011204	JP 2000-513546	19980925

PRIORITY APPLN. INFO.: NZ 1997-328853 A 19970926
WO 1998-NZ145 W 19980925

AB This invention is directed to new therapeutic uses which involve the stimulation of **chondrocyte proliferation**. More particularly, it is directed to the use of **amylin** and adrenomedullin and their analogs as agents which stimulate

chondrocyte proliferation and which therefore have utility in the **treatment** of **cartilage** disorders and/or **cartilage** mediated **bone growth**. Thus, **amylin**(1-8) (10-8M) stimulated **chondrocyte proliferation**, increasing cell nos. from 3.23 x 104 to 3.63 x 104 as well as increasing thymidine incorporation (i.e. DNA synthesis) from 26859 .+-. 423 to 28932 .+-. 628 dpm.

L228 ANSWER 16 OF 20 PHIN COPYRIGHT 2003 PJB on STN

ACCESSION NUMBER: 1998:15417 PHIN
DOCUMENT NUMBER: B00592190
DATA ENTRY DATE: 1 Jul 1998
TITLE: The Phase III Club
SOURCE: Bioventure-View (1998) No. 1307 p4
DOCUMENT TYPE: Newsletter
FILE SEGMENT: FULL

L228 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1998:679141 CAPLUS
DOCUMENT NUMBER: 130:20821
TITLE: Systemic administration of **amylin** increases **bone** mass, linear growth, and adiposity in adult male mice
AUTHOR(S): Cornish, Jillian; Callon, Karen E.; King, Alan R.; Cooper, Garth J. S.; Reid, Ian R.
CORPORATE SOURCE: Department of Medicine, University of Auckland, Auckland, 92019, N. Z.
SOURCE: American Journal of Physiology (1998), 275(4, Pt. 1), E694-E699
CODEN: AJPHAP; ISSN: 0002-9513
PUBLISHER: American Physiological Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB **Amylin** is a peptide hormone cosecreted with insulin from the pancreatic .beta.-cells that can act as an osteoblast mitogen and as an inhibitor of **bone** resorption. The effects on bone of its systemic administration are uncertain. The present study addresses this question in adult male mice that were given daily s.c. injections of amylin (10.5 .mu.g) or vehicle for 4 wk. Histomorphometric indexes of **bone** formation increased 30-100% in the **amylin-treated** group, whereas resorption indexes were reduced by .apprx.70%. Total **bone** vol. in the proximal **tibia** was 13.5% in control animals and 23.0% in those receiving **amylin**. Cortical width, **tibial** growth plate width, **tibial** length, body wt., and fat mass were all increased in the **amylin-treated** group. It is concluded that systemic administration of **amylin** increases skeletal mass and linear **bone** growth. This peptide has potential as a therapy for osteoporosis if its bone effects can be dissocd. from those on soft tissue mass.
REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L228 ANSWER 18 OF 20 COPYRIGHT 2003 Gale Group on STN

ACCESSION NUMBER: 95:110634 NLDB
TITLE: GENZYME TISSUE, AMYLIN, VICAL GROSS $105M FROM OFFERINGS
SOURCE: BIOWORLD Today, (25 Sep 1995) Vol. 6, No. 183.
PUBLISHER: American Health Consultants
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 333

L228 ANSWER 19 OF 20 DISSABS COPYRIGHT (C) 2003 ProQuest Information and Learning Company; All Rights Reserved on STN

ACCESSION NUMBER: 95:2733 DISSABS Order Number: AAR9430910
TITLE: ROLES OF THE NUCLEATIONAL CORE COMPLEX AND COLLAGENS (TYPE II AND X) IN CALCIFICATION OF **GROWTH** PLATE MATRIX VESICLES AND STUDIES ON CALCIFYING **CHONDROCYTES** IN CULTURE
AUTHOR: MWALE, FACKSON [PH.D.]; ISHIKAWA, YOSHINORI [advisor]
CORPORATE SOURCE: UNIVERSITY OF SOUTH CAROLINA (0202)
SOURCE: Dissertation Abstracts International, (1994) Vol. 55, No. 7B, p. 2710. Order No.: AAR9430910. 230 pages.
DOCUMENT TYPE: Dissertation
FILE SEGMENT: DAI
LANGUAGE: English
ENTRY DATE: Entered STN: 19950111
Last Updated on STN: 19950111

AB Matrix vesicles (MV) have been shown to initiate mineralization in cartilage and other vertebrate tissues. However, little is known about the factors that regulate mineralization of MV. Recent studies have shown that a preformed nucleational core which mainly consists of Ca$\sp{2+}$-PS-Pi complex, is necessary for the rapid accumulation of Ca$\sp{2+}$ by MV in vitro. In this comparative study, three different enzyme digestion methods are used to release MV: TCRMV (trypsin/collagenase), HRMV (hyaluronidase), or HCRMV (hyaluronidase/collagenase), TCRMV pellets contained type II and X collagens, while HRMV and HCRMV did not, and only TCRMV showed a high uptake of Ca$\sp{2+}.$ However, binding of native type II collagen stimulated HRMV and HCRMV uptake of Ca$\sp{2+}.$

Our recent development of cultures of epiphyseal **growth** plate **chondrocytes** that are capable of mineralizing in the absence of b-glycerophosphate provides a useful model for studying the direct effect of osteotropic agents on skeletal cells. The **chondrocytes** reach confluence and become hypertrophic after 2 weeks in culture, after which they form nodules and cellular blebs and then induce mineral deposition. After **treatment** with sodium hypochlorite, the mineralized cell layer revealed numerous calcospherite-like structures arranged in the concave lacunar wall. This is the first time these structures have been observed in culture.

The regulatory function of **amylin** (new member of calcitonin/CGRP) on mineralization of **growth** plate **chondrocytes** and collagen synthesis was studied. **Amylin** stimulates alkaline phosphatase activity and mineral formation at early time points. **Amylin** binds to annexin V which, in turn, acts as a calcium channel in MV. Rat **amylin** fragment (8-37), however, showed no effect on mineralization of **chondrocytes** and did not bind to annexin V, indicating a possible role for the NH$\sb2$-terminal region of **amylin** for biological activity. **Amylin** also stimulates type II collagen synthesis in sternal **chondrocytes** in serum-free medium. These findings implicate **amylin** in processes regulating endochondral **bone** formation.

L228 ANSWER 20 OF 20 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
ACCESSION NUMBER: AAY01705 peptide DGENE
TITLE: **Treating** patient to stimulate **chondrocyte proliferation** in vivo comprising administration of **amylin**, adrenomedullin or ligand **growth** to stimulate receptor useful for **cartilage/bone** repair
INVENTOR: Cornish J; Reid I R
PATENT ASSIGNEE: (AUCK-N)AUCKLAND UNISERVICES LTD.
PATENT INFO: WO 9916406 A2 19990408 25p
APPLICATION INFO: WO 1998-NZ145 19980925
PRIORITY INFO: NZ 1997-328853 19970926
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1999-277029 [23]
DESCRIPTION: Peptide sequence of amylin.
AN AAY01705 peptide DGENE

AB The present sequence represents an **amylin** protein. The specification describes a method for increasing the active concentration of **amylin**, adrenomedullin or ligand receptor within a patient to stimulate **chondrocyte proliferation**. The method is useful for **treating** a patient to stimulate **cartilage growth** and repair and **bone growth** (especially effecting the lineal **growth** of **bone**) in vivo through stimulation of **chondrocyte proliferation**.

=>

WEST Search History

DATE: Thursday, November 13, 2003

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB,EPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES; OP=ADJ			
L2	L1 and treat$ and administ$	102	L2
L1	amylin same (bone or chondrocyte or cartilage or tibia$ or epiphysca$)	108	L1

END OF SEARCH HISTORY

WEST Search History

DATE: Monday, November 10, 2003

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB,EPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES; OP=ADJ			
L9	amylin? and treat$ and chondrocyte	0	L9
L8	amylin? and treat$ same chondrocyte	0	L8
L7	amylin? and treat$	52	L7
L6	amylin? same treat$ and chondrocyte	0	L6
L5	amylin? and (cartilage adj (growth or repair))	0	L5
L4	amylin? and (chondrocyte adj proliferation)	0	L4
L3	amylin? same (chondrocyte adj proliferation)	0	L3
L2	amylin? same (chondrocyte adj proliferation or (cartilage adj (growth or repair)))	0	L2
L1	6468987.pn. or 6187558.pn.	4	L1

END OF SEARCH HISTORY

WEST

Generate Collection | Print

Search Results - Record(s) 1 through 102 of 102 returned.

1. Document ID: US 20030211127 A1

L2: Entry 1 of 102 File: PGPB Nov 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030211127
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030211127 A1

TITLE: Controlled dissolution crosslinked prote in crystals

PUBLICATION-DATE: November 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Margolin, Alexey L.	Newton	MA	US	
Persichetti, Rose A.	Stow	MA	US	
St. Clair, Nancy L.	Durham	NC	US	
Khalaf, Nazer K.	Worcester	MA	US	
Shenoy, Bhami C.	Woburn	MA	US	

US-CL-CURRENT: 424/401; 424/130.1, 424/185.1, 424/236.1, 424/85.1, 424/94.1, 435/195, 435/198, 435/200, 510/226, 510/330 , 514/12, 514/3, 530/303, 530/313, 530/350, 530/351, 530/389.1, 530/399

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

2. Document ID: US 20030198954 A1

L2: Entry 2 of 102 File: PGPB Oct 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030198954
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030198954 A1

TITLE: Human cDNAs and proteins and uses thereof

PUBLICATION-DATE: October 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bejanin, Stephane	Paris		FR	
Tanaka, Hiroaki	Antony		FR	

US-CL-CURRENT: 435/6; 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

3. Document ID: US 20030198601 A1

L2: Entry 3 of 102 File: PGPB Oct 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030198601
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030198601 A1

TITLE: Compositions and methods for the pulmonary delivery of aerosolized medicaments

PUBLICATION-DATE: October 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Platz, Robert M.	Half Moon Bay	CA	US	
Patton, John S.	Portola Valley	CA	US	
Foster, Linda	Sunnyvale	CA	US	
Eljamal, Mohammed	Tripoli		LB	

US-CL-CURRENT: 424/46; 424/85.4, 514/12, 514/3, 514/44, 514/56

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PDMC | Draw Desc | Image

4. Document ID: US 20030185765 A1

L2: Entry 4 of 102 File: PGPB Oct 2, 2003

PGPUB-DOCUMENT-NUMBER: 20030185765
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030185765 A1

TITLE: Composition for pulmonary administration comprising a drug and a hydrophobic amino acid

PUBLICATION-DATE: October 2, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Platz, Robert M.	Half Moon Bay	CA	US	
Patton, John S.	Portola Valley	CA	US	
Foster, Linda C.	Sunnyvale	CA	US	
Eljamal, Mohammed	Tripoli		LB	

US-CL-CURRENT: 424/46; 514/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PDMC | Draw Desc | Image

5. Document ID: US 20030180332 A1

L2: Entry 5 of 102 File: PGPB Sep 25, 2003

PGPUB-DOCUMENT-NUMBER: 20030180332
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030180332 A1

TITLE: Novel pharmaceutical composition

PUBLICATION-DATE: September 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rimpler, Stephan	Hilden		DE	
Grapatin, Sabine	Langenfeld		DE	
Krein, Cliff	Overath		DE	
Thelen, Markus	Monheim		DE	

US-CL-CURRENT: 424/400

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

6. Document ID: US 20030175285 A1

L2: Entry 6 of 102 File: PGPB Sep 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030175285
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030175285 A1

TITLE: Molecule of pharmaceutical interest comprising at its n-terminal a glutamic acid or a glutamine in the form of a physiologically acceptable strong acid

PUBLICATION-DATE: September 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Klinguer-Hamour, Christine	Groisy		FR	
Nathalie, Corvaia	Genevois		FR	
Alain, Beck	Saleve		FR	
Liliane, Goetsch	Ayze		FR	

US-CL-CURRENT: 424/185.1; 514/12, 530/350, 530/359

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

7. Document ID: US 20030175239 A1

L2: Entry 7 of 102 File: PGPB Sep 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030175239
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030175239 A1

TITLE: Stabilized protein crystals, formulations comprising them and methods of making them

PUBLICATION-DATE: September 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Margolin, Alexey L.	Newton	MA	US	
Khalaf, Nazar K.	Worcester	MA	US	
St. Clair, Nancy L.	Ann Arbor	MI	US	
Rakestraw, Scott L.	Newark	DE	US	
Shenoy, Bhami C.	Woburn	MA	US	

US-CL-CURRENT: 424/85.1; 424/130.1, 424/185.1, 424/85.2, 435/189, 435/198, 435/228, 514/2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PDMC | Draw Desc | Image

8. Document ID: US 20030170628 A1

L2: Entry 8 of 102 File: PGPB Sep 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030170628
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030170628 A1

TITLE: Human cDNAs and proteins and uses thereof

PUBLICATION-DATE: September 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bejanin, Stephane	Paris		FR	
Tanaka, Hiroaki	Antony		FR	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 435/7.1, 530/350, 530/388.1, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PDMC | Draw Desc | Image

9. Document ID: US 20030162186 A1

L2: Entry 9 of 102 File: PGPB Aug 28, 2003

PGPUB-DOCUMENT-NUMBER: 20030162186
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030162186 A1

TITLE: Human cDNAs and proteins and uses thereof

PUBLICATION-DATE: August 28, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bejanin, Stephane	Paris		FR	
Tanaka, Hiroaki	Antony		FR	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PDMC | Draw Desc | Image

10. Document ID: US 20030158159 A1

L2: Entry 10 of 102 File: PGPB Aug 21, 2003

PGPUB-DOCUMENT-NUMBER: 20030158159
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030158159 A1

TITLE: Treatment of subnormal bone mineral density

PUBLICATION-DATE: August 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schwartz, Kenneth E.	San Mateo	CA	US	

US-CL-CURRENT: 514/170; 514/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | Draw Desc | Image

11. Document ID: US 20030157485 A1

L2: Entry 11 of 102 File: PGPB Aug 21, 2003

PGPUB-DOCUMENT-NUMBER: 20030157485
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030157485 A1

TITLE: Human cDNAs and proteins and uses thereof

PUBLICATION-DATE: August 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bejanin, Stephane	Paris		FR	
Tanaka, Hiroaki	Antony		FR	

US-CL-CURRENT: 435/6; 435/226, 435/320.1, 435/325, 435/69.1, 435/7.2, 530/388.26, 536/23.2, 800/8

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | Draw Desc | Image

12. Document ID: US 20030149027 A1

L2: Entry 12 of 102 File: PGPB Aug 7, 2003

PGPUB-DOCUMENT-NUMBER: 20030149027
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030149027 A1

TITLE: 1,5-benzodiazepine compounds, their production and use

PUBLICATION-DATE: August 7, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Oi, Satoru	Nara-shi		JP	
Suzuki, Nobuhiro	Tsukuba-shi		JP	
Matsumoto, Takahiro	Kawabe-gun		JP	

US-CL-CURRENT: 514/221; 540/518

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | Draw Desc | Image

13. Document ID: US 20030129141 A1

L2: Entry 13 of 102 File: PGPB Jul 10, 2003

PGPUB-DOCUMENT-NUMBER: 20030129141
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030129141 A1

TITLE: Composition for pulmonary administration comprising a drug and a hydrophobic amino acid

PUBLICATION-DATE: July 10, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Platz, Robert M.	Half Moon Bay	CA	US	
Patton, John S.	Portola Valley	CA	US	
Foster, Linda C.	Sunnyvale	CA	US	
Eljamal, Mohammed	Tripoli		LB	

US-CL-CURRENT: 424/46; 514/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | Draw Desc | Image

14. Document ID: US 20030108743 A1

L2: Entry 14 of 102 File: PGPB Jun 12, 2003

PGPUB-DOCUMENT-NUMBER: 20030108743
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030108743 A1

TITLE: Coated particles, methods of making and using

PUBLICATION-DATE: June 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Anderson, David M.	Colonial Heights	VA	US	

US-CL-CURRENT: 428/402.24

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | Draw Desc | Image

15. Document ID: US 20030108624 A1

L2: Entry 15 of 102 File: PGPB Jun 12, 2003

PGPUB-DOCUMENT-NUMBER: 20030108624
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030108624 A1

TITLE: Compositions and methods for prevention and treatment of chronic diseases and disorders including the complications of diabetes mellitus

PUBLICATION-DATE: June 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kosbab, John V.	Dillon	CO	US	

US-CL-CURRENT: 424/729; 424/732, 424/770, 514/455, 514/474, 514/54, 514/62

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | Draw Desc | Image

16. Document ID: US 20030096247 A1

L2: Entry 16 of 102 File: PGPB May 22, 2003

PGPUB-DOCUMENT-NUMBER: 20030096247
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030096247 A1

TITLE: Human cDNAs and proteins and uses thereof

PUBLICATION-DATE: May 22, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bejanin, Stephane	Paris		FR	
Tanaka, Hiroaki	Antony		FR	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2, 800/8

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | Draw Desc | Image

17. Document ID: US 20030092800 A1

L2: Entry 17 of 102 File: PGPB May 15, 2003

PGPUB-DOCUMENT-NUMBER: 20030092800
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030092800 A1

TITLE: Ionic molecular conjugates of n-acylated derivatives of poly(2-amino-2-deoxy-d-glucose) and polypeptides

PUBLICATION-DATE: May 15, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Shalaby, Shalaby W.	Pendleton	SC	US	
Jackson, Steven A.	Holliston	MA	US	
Ignatious, Francis X.	Millville	MA	US	
Moreau, Jacques-Pierre	Upton	MA	US	
Russell, Ruth M.	Dublin		IE	

US-CL-CURRENT: 524/17

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

18. Document ID: US 20030092606 A1

L2: Entry 18 of 102 File: PGPB May 15, 2003

PGPUB-DOCUMENT-NUMBER: 20030092606
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030092606 A1

TITLE: Formulations for amylin agonist peptides

PUBLICATION-DATE: May 15, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
L'Italien, James	Del Mar	CA	US	
Stetsko, Gregg	San Diego	CA	US	

US-CL-CURRENT: 514/2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

19. Document ID: US 20030092011 A1

L2: Entry 19 of 102 File: PGPB May 15, 2003

PGPUB-DOCUMENT-NUMBER: 20030092011
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030092011 A1

TITLE: Human cDNAs and proteins and uses thereof

PUBLICATION-DATE: May 15, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bejanin, Stephane	Paris		FR	
Tanaka, Hiroaki	Antony		FR	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 435/7.9, 536/23.2, 800/3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

20. Document ID: US 20030086877 A1

L2: Entry 20 of 102 File: PGPB May 8, 2003

PGPUB-DOCUMENT-NUMBER: 20030086877
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030086877 A1

TITLE: Devices, compositions and methods for the pulmonary delivery of aerosolized medicaments

PUBLICATION-DATE: May 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Platz, Robert M.	Half Moon Bay	CA	US	
Patton, John S.	San Carlos	CA	US	
Foster, Linda	Sunnyvale	CA	US	
Eljamal, Mohammed	San Jose	CA	US	

US-CL-CURRENT: 424/46

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | Drawing Desc | Image

21. Document ID: US 20030077756 A1

L2: Entry 21 of 102 File: PGPB Apr 24, 2003

PGPUB-DOCUMENT-NUMBER: 20030077756
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030077756 A1

TITLE: Identification and modification of immunodominant epitopes in polypeptides

PUBLICATION-DATE: April 24, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Koren, Eugen	San Francisco	CA	US	
Lowe, John Hok Nin	Pleasanton	CA	US	

US-CL-CURRENT: 435/70.21; 435/326, 435/69.1, 435/7.21

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | Drawing Desc | Image

22. Document ID: US 20030072803 A1

L2: Entry 22 of 102 File: PGPB Apr 17, 2003

PGPUB-DOCUMENT-NUMBER: 20030072803
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030072803 A1

TITLE: Sustained-release delayed gels

PUBLICATION-DATE: April 17, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Goldenberg, Merrill Seymour	Thousand Oaks	CA	US	
Beekman, Alice C.	Thousand Oaks	CA	US	
Gu, Jian Hua	Thousand Oaks	CA	US	

US-CL-CURRENT: 424/468

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

23. Document ID: US 20030068279 A1

L2: Entry 23 of 102 File: PGPB Apr 10, 2003

PGPUB-DOCUMENT-NUMBER: 20030068279
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030068279 A1

TITLE: Devices, compositions and methods for the pulmonary delivery of aerosolized medicaments

PUBLICATION-DATE: April 10, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Platz, Robert M.	Half Moon Bay	CA	US	
Patton, John S.	San Carlos	CA	US	
Foster, Linda	Sunnyvale	CA	US	
Eljamal, Mohammed	San Jose	CA	US	

US-CL-CURRENT: 424/46

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

24. Document ID: US 20030064918 A1

L2: Entry 24 of 102 File: PGPB Apr 3, 2003

PGPUB-DOCUMENT-NUMBER: 20030064918
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030064918 A1

TITLE: Compounds and uses thereof in treating bone disorders

PUBLICATION-DATE: April 3, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Reid, Ian Reginald	Auckland	CA	NZ	
Cornish, Jillian	Auckland		NZ	
Cooper, Garth James Smith	Auckland		NZ	
Coy, David H.	New Orleans		US	

US-CL-CURRENT: 514/9; 530/317

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

25. Document ID: US 20030027248 A1

L2: Entry 25 of 102 File: PGPB Feb 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030027248
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030027248 A1

TITLE: Human cDNAs and proteins and uses thereof

PUBLICATION-DATE: February 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bejanin, Stephane	Paris		FR	
Tanaka, Hiroaki	Antony		FR	

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 435/6, 530/350, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

26. Document ID: US 20030027161 A1

L2: Entry 26 of 102 File: PGPB Feb 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030027161
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030027161 A1

TITLE: Human cDNAs and proteins and uses thereof

PUBLICATION-DATE: February 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bejanin, Stephane	Paris		FR	
Tanaka, Hiroaki	Antony		FR	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2, 800/8

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

27. Document ID: US 20030026812 A1

L2: Entry 27 of 102 File: PGPB Feb 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030026812
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030026812 A1

TITLE: METHODS FOR TREATING OBESITY

PUBLICATION-DATE: February 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
DUFT, BRADFORD J.	SANTE FE	CA	US	
KOLTERMAN, ORVILLE G.	POWAY	CA	US	

US-CL-CURRENT: 424/198.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PrintC | Draw Desc | Image

28. Document ID: US 20030022242 A1

L2: Entry 28 of 102 File: PGPB Jan 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030022242
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030022242 A1

TITLE: Particles with improved solubilization capacity

PUBLICATION-DATE: January 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Anderson, David	Colonial Heights	VA	US	

US-CL-CURRENT: 435/7.1; 424/490

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PrintC | Draw Desc | Image

29. Document ID: US 20020187923 A1

L2: Entry 29 of 102 File: PGPB Dec 12, 2002

PGPUB-DOCUMENT-NUMBER: 20020187923
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020187923 A1

TITLE: NOVEL AMYLIN AGONIST PEPTIDES AND USES THEREFOR

PUBLICATION-DATE: December 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
GAETA, LAURA S. L.	LA JOLLA	CA	US	
JONES, HOWARD	POWAY	CA	US	
ALBRECHT, ELISABETH	SAN DIEGO	CA	US	

US-CL-CURRENT: 514/2; 514/12, 530/324

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PrintC | Draw Desc | Image

30. Document ID: US 20020187523 A1

L2: Entry 30 of 102 File: PGPB Dec 12, 2002

PGPUB-DOCUMENT-NUMBER: 20020187523
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020187523 A1

TITLE: Extracellular signaling molecules

PUBLICATION-DATE: December 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Tang, Y. Tom	San Jose	CA	US	
Yue, Henry	Sunnyvale	CA	US	
Lal, Preeti	Santa Clara	CA	US	
Burford, Neil	Durham	CT	US	
Bandman, Olga	Mountain View	CA	US	
Baughn, Mariah R.	San Leandro	CA	US	
Azimzai, Yalda	Castro Valley	CA	US	
Lu, Dyung Aina M.	San Jose	CA	US	
Arvizu, Chandra	Menlo Park	CA	US	

US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1, 435/325, 530/350, 536/23.5, 800/8

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PWIC | Draw Desc | Image

31. Document ID: US 20020182650 A1

L2: Entry 31 of 102 File: PGPB Dec 5, 2002

PGPUB-DOCUMENT-NUMBER: 20020182650
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020182650 A1

TITLE: Inhibitors of binding between proteins and macromolecular ligands

PUBLICATION-DATE: December 5, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sworin, Michael	Tyngsboro	MA	US	
Jenson, James C.	Sudbury	MA	US	

US-CL-CURRENT: 435/7.9; 514/1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PWIC | Draw Desc | Image

32. Document ID: US 20020168406 A1

L2: Entry 32 of 102 File: PGPB Nov 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020168406
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020168406 A1

TITLE: Biodegradable sustained-release alginate gels

PUBLICATION-DATE: November 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Goldenberg, Merrill Seymour	Thousand Oaks	CA	US	
Gu, Jian Hua	Thousand Oaks	CA	US	

US-CL-CURRENT: 424/468

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KMC | Draw Desc | Image

33. Document ID: US 20020142456 A1

L2: Entry 33 of 102 File: PGPB Oct 3, 2002

PGPUB-DOCUMENT-NUMBER: 20020142456
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020142456 A1

TITLE: Canine OB protein compositions and methods

PUBLICATION-DATE: October 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hernday, Natasha	Ventura	CA	US	

US-CL-CURRENT: 435/350; 435/243, 435/320.1, 435/325, 435/69.1, 435/810, 530/324, 530/387.7, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KMC | Draw Desc | Image

34. Document ID: US 20020137156 A1

L2: Entry 34 of 102 File: PGPB Sep 26, 2002

PGPUB-DOCUMENT-NUMBER: 20020137156
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020137156 A1

TITLE: CONTROLLED DISSOLUTION CROSSLINKED PROTEIN CRYSTALS

PUBLICATION-DATE: September 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
MARGOLIN, ALEXEY L.	NEWTON	MA	US	
PERSICHETTI, ROSE A.	STOW	MA	US	
ST. CLAIR, NANCY L.	ANN ARBOR	MI	US	
KHALAF, NAZER K.	Worchester	MA	US	
SHENOY, BHAMI C.	Woburn	MA	US	

US-CL-CURRENT: 435/174

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

35. Document ID: US 20020127188 A1

L2: Entry 35 of 102 File: PGPB Sep 12, 2002

PGPUB-DOCUMENT-NUMBER: 20020127188
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020127188 A1

TITLE: Composition for pulmonary administration comprising a drug and a hydrophobic amino acid

PUBLICATION-DATE: September 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Platz, Robert M.	Half Moon Bay	CA	US	
Patton, John S.	Portola Valley	CA	US	
Foster, Linda	Sunnyvale	CA	US	
Eljamal, Mohammed	Tripoli		LB	

US-CL-CURRENT: 424/46

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

36. Document ID: US 20020122827 A1

L2: Entry 36 of 102 File: PGPB Sep 5, 2002

PGPUB-DOCUMENT-NUMBER: 20020122827
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020122827 A1

TITLE: Dispersible macromolecule compositions and methods for their preparation and use

PUBLICATION-DATE: September 5, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Platz, Robert	Half Moon Bay	CA	US	
Brewer, Thomas	Walnut Creek	CA	US	
Boardman, Terrence	Palo Alto	CA	US	

US-CL-CURRENT: 424/489; 424/499

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

37. Document ID: US 20020119117 A1

L2: Entry 37 of 102 File: PGPB Aug 29, 2002

PGPUB-DOCUMENT-NUMBER: 20020119117
PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020119117 A1

TITLE: Modulated release particles for aerosol delivery

PUBLICATION-DATE: August 29, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Zhu, Yaping	Highland Park	NJ	US	
Stefanos, Simon G.	Morris Plains	NJ	US	
Sun, John Z.	Edison	NJ	US	
Adjei, Akwete L.	Bridgewater	NY	US	

US-CL-CURRENT: 424/85.1; 424/184.1, 424/46, 424/85.2, 424/85.5, 424/94.1, 514/12, 514/3, 514/44, 514/56

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PDMC | Draw Desc | Image

38. Document ID: US 20020117170 A1

L2: Entry 38 of 102 File: PGPB Aug 29, 2002

PGPUB-DOCUMENT-NUMBER: 20020117170
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020117170 A1

TITLE: Compositions and methods for the pulmonary delivery of aerosolized macromolecules

PUBLICATION-DATE: August 29, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Platz, Robert M.	Half Moon Bay	CA	US	
Patton, John S.	San Carlos	CA	US	
Foster, Linda C.	Sunnyvale	CA	US	
Eljamal, Mohammed	San Jose	CA	US	

US-CL-CURRENT: 128/200.14

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PDMC | Draw Desc | Image

39. Document ID: US 20020110539 A1

L2: Entry 39 of 102 File: PGPB Aug 15, 2002

PGPUB-DOCUMENT-NUMBER: 20020110539
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020110539 A1

TITLE: Modulated release particles for lung delivery

PUBLICATION-DATE: August 15, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Zhu, Yaping	Highland Park	NJ	US	
Stefanos, Simon G.	Morris Plains	NJ	US	
Kline, Lukeysha	Toms River	NJ	US	
Adjei, Akwete L.	Bridgewater	NJ	US	

US-CL-CURRENT: 424/85.1; 424/493, 514/44, 514/54

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PDMC | Draw Desc | Image

40. Document ID: US 20020110528 A1

L2: Entry 40 of 102 File: PGPB Aug 15, 2002

PGPUB-DOCUMENT-NUMBER: 20020110528
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020110528 A1

TITLE: Modulated release particles for aerosol delivery

PUBLICATION-DATE: August 15, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Zhu, Yaping	Highland Park	NJ	US	
Stefanos, Simon	Morris Plains	NJ	US	
Adjei, Akwete L.	Bridgewater	NJ	US	

US-CL-CURRENT: 424/46

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PDMC | Draw Desc | Image

41. Document ID: US 20020110527 A1

L2: Entry 41 of 102 File: PGPB Aug 15, 2002

PGPUB-DOCUMENT-NUMBER: 20020110527
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020110527 A1

TITLE: Modulated release particles for lung delivery

PUBLICATION-DATE: August 15, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Zhu, Yaping	Highland Park	NJ	US	
Adjei, Akwete L.	Bridgewater	NJ	US	

US-CL-CURRENT: 424/46

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PDMC | Draw Desc | Image

42. Document ID: US 20020110526 A1

L2: Entry 42 of 102 File: PGPB Aug 15, 2002

PGPUB-DOCUMENT-NUMBER: 20020110526
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020110526 A1

TITLE: Modulated release particles for lung delivery

PUBLICATION-DATE: August 15, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Zhu, Yaping	Highland Park	NJ	US	
Stefanos, Simon G.	Morris Plains	NJ	US	
Kline, Lukeysha	Toms River	NJ	US	
Adjei, Akwete L.	Bridgewater	NJ	US	

US-CL-CURRENT: 424/46; 424/185.1, 424/85.2, 424/85.5, 424/94.1, 514/2, 514/3, 514/44, 514/54

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PinMC | Draw Desc | Image

43. Document ID: US 20020110525 A1

L2: Entry 43 of 102 File: PGPB Aug 15, 2002

PGPUB-DOCUMENT-NUMBER: 20020110525
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020110525 A1

TITLE: Modulated release particles for lung delivery

PUBLICATION-DATE: August 15, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Adjei, Akwete L.	Bridgewater	NJ	US	
Zhu, Yaping	Highland Park		NJ	

US-CL-CURRENT: 424/46; 514/54

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PinMC | Draw Desc | Image

44. Document ID: US 20020098206 A1

L2: Entry 44 of 102 File: PGPB Jul 25, 2002

PGPUB-DOCUMENT-NUMBER: 20020098206
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020098206 A1

TITLE: IONIC MOLECULAR CONJUGATES OF N-ACYLATED DERIVATIVES OF POLY(2-AMINO-2-DEOXY-D-GLUCOSE) AND POLYPEPTIDES

PUBLICATION-DATE: July 25, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
SHALABY, SHALABY W.	ANDERSON	SC	US	
JACKSON, STEVEN A.	HOLLISTON	MA	US	
IGNATIOUS, FRANCIS X.	MILLVILLE	MA	US	
MOREAU, JACQUES-PIERRE	UPTON	MA	US	
RUSSELL, RUTH M.	DUBLIN		IE	

US-CL-CURRENT: 424/400

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PwwC | Draw Desc | Image

45. Document ID: US 20020045582 A1

L2: Entry 45 of 102 File: PGPB Apr 18, 2002

PGPUB-DOCUMENT-NUMBER: 20020045582
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020045582 A1

TITLE: STABILIZED PROTEIN CRYSTALS FORMULATIONS CONTAINING THEM AND METHODS OF MAKING THEM

PUBLICATION-DATE: April 18, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
MARGOLIN, ALEXEY L.	NEWTON	MA	US	
KHALAF, NAZAR K.	WORCESTER	MA	US	
CLAIR, NANCY L. ST.	ANN ARBOR	MI	US	
RAKESTRAW, SCOTT L.	NEWARK	DE	US	
SHENOY, BHAMI C.	WOBURN	MA	US	

US-CL-CURRENT: 514/21; 424/186.1, 424/190.1, 424/198.1, 424/400, 424/426, 424/85.1, 435/183, 514/2, 514/44, 530/362, 530/387.1, 536/23.1, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PwwC | Draw Desc | Image

46. Document ID: US 20020039567 A1

L2: Entry 46 of 102 File: PGPB Apr 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020039567
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020039567 A1

TITLE: Methods of treating bone or cartilage conditions by the administration of creatine

PUBLICATION-DATE: April 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wallimann, Theo	Kindhausen		CH	
Gerber, Isabel	Pieterlen		CH	

US-CL-CURRENT: 424/85.1; 424/93.7, 424/94.63, 514/114, 514/167, 514/171, 514/2, 514/48, 514/51, 514/54, 514/561

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PDMC | Draw Desc | Image

47. Document ID: US 20020019352 A1

L2: Entry 47 of 102 File: PGPB Feb 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020019352
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020019352 A1

TITLE: STABLE, ACTIVE, HUMAN OB PROTEIN COMPOSITIONS AND METHODS

PUBLICATION-DATE: February 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
BREMS, DAVID N.	NEWBURY PARK	CA	US	
FRENCH, DONNA L.	MOORPARK	CA	US	
SPEED, MARGARET A.	NEWBURY PARK	CA	US	

US-CL-CURRENT: 514/14; 514/2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PDMC | Draw Desc | Image

48. Document ID: US 20020001619 A1

L2: Entry 48 of 102 File: PGPB Jan 3, 2002

PGPUB-DOCUMENT-NUMBER: 20020001619
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020001619 A1

TITLE: SUSTAINED-RELEASE ALGINATE GELS

PUBLICATION-DATE: January 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
GOLDENBERG, MERRILL SEYMOUR	THOUSAND OAKS	CA	US	
BEEKMAN, ALICE C.	THOUSAND OAKS	CA	US	

US-CL-CURRENT: 424/484; 424/485, 424/488, 514/779, 514/944

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PDMC | Draw Desc | Image

49. Document ID: US 20010043934 A1

L2: Entry 49 of 102 File: PGPB Nov 22, 2001

PGPUB-DOCUMENT-NUMBER: 20010043934
PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20010043934 A1

TITLE: FORMULATIONS FOR AMYLIN AGONIST PEPTIDES

PUBLICATION-DATE: November 22, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
L'ITALIEN, JAMES	DEL MAR	CA	US	
MUSUNURI, SHANKAR	EXTON	PA	US	
RUBY, KALE	SAN DIEGO	CA	US	

US-CL-CURRENT: 424/400

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PwMC | Draw Desc | Image

50. Document ID: US 20010031744 A1

L2: Entry 50 of 102 File: PGPB Oct 18, 2001

PGPUB-DOCUMENT-NUMBER: 20010031744
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010031744 A1

TITLE: Compositions and methods for prevention and treatment of chronic diseases and disorders including the complications of diabetes mellitus

PUBLICATION-DATE: October 18, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kosbab, John V.	Dillon	CO	US	

US-CL-CURRENT: 514/54; 424/729, 424/732, 424/770, 514/458, 514/474, 514/62, 514/725

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PwMC | Draw Desc | Image

51. Document ID: US 6638621 B2

L2: Entry 51 of 102 File: USPT Oct 28, 2003

US-PAT-NO: 6638621
DOCUMENT-IDENTIFIER: US 6638621 B2

TITLE: Coated particles, methods of making and using

DATE-ISSUED: October 28, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Anderson; David	Colonial Heights	VA		

US-CL-CURRENT: 428/402.24; 424/422, 424/426, 424/450, 435/176

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PwMC | Draw Desc | Image

52. Document ID: US 6610824 B2

L2: Entry 52 of 102 File: USPT Aug 26, 2003

US-PAT-NO: 6610824
DOCUMENT-IDENTIFIER: US 6610824 B2

TITLE: Amylin agonist peptides and uses therefor

DATE-ISSUED: August 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gaeta; Laura S. L.	La Jolla	CA		
Jones; Howard	Poway	CA		
Albrecht; Elisabeth	San Diego	CA		

US-CL-CURRENT: 530/324; 530/300

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PDMC | Draw Desc | Image

53. Document ID: US 6608029 B1

L2: Entry 53 of 102 File: USPT Aug 19, 2003

US-PAT-NO: 6608029
DOCUMENT-IDENTIFIER: US 6608029 B1

TITLE: Methods for regulating gastrointestinal motility

DATE-ISSUED: August 19, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kolterman; Orville G.	Poway	CA		
Young; Andrew A.	Alpine	CA		
Rink; Timothy J.	La Jolla	CA		
Keating Brown; Kathleen Ann	Wake Forest	NC		

US-CL-CURRENT: 514/12; 514/13, 514/21

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PDMC | Draw Desc | Image

54. Document ID: US 6605591 B1

L2: Entry 54 of 102 File: USPT Aug 12, 2003

US-PAT-NO: 6605591
DOCUMENT-IDENTIFIER: US 6605591 B1

TITLE: Treatment of subnormal bone mineral density

DATE-ISSUED: August 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schwartz; Kenneth E.	San Mateo	CA		

US-CL-CURRENT: 514/2; 435/58, 514/178, 514/179, 514/808, 514/9, 530/307, 530/317, 552/542, 552/615

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PwwC | Draw Desc | Image

55. Document ID: US 6596262 B2

L2: Entry 55 of 102 File: USPT Jul 22, 2003

US-PAT-NO: 6596262
DOCUMENT-IDENTIFIER: US 6596262 B2

TITLE: Modulated release particles for aerosol delivery

DATE-ISSUED: July 22, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Zhu; Yaping	Highland Park	NJ		
Stefanos; Simon G.	Morris Plains	NJ		
Sun; John Z.	Edison	NJ		
Adjei; Akwete L.	Bridgewater	NJ		

US-CL-CURRENT: 424/45; 424/489, 514/1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PwwC | Draw Desc | Image

56. Document ID: US 6592904 B2

L2: Entry 56 of 102 File: USPT Jul 15, 2003

US-PAT-NO: 6592904
DOCUMENT-IDENTIFIER: US 6592904 B2

TITLE: Dispersible macromolecule compositions and methods for their preparation and use

DATE-ISSUED: July 15, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Platz; Robert M.	Half Moon Bay	CA		
Brewer; Thomas K.	Booneville	CA		
Boardman; Terence D.	Los Altos	CA		

US-CL-CURRENT: 424/491; 264/12, 264/5, 424/489, 424/497, 424/499, 514/2, 514/3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PwwC | Draw Desc | Image

57. Document ID: US 6582728 B1

L2: Entry 57 of 102 File: USPT Jun 24, 2003

US-PAT-NO: 6582728
DOCUMENT-IDENTIFIER: US 6582728 B1

TITLE: Spray drying of macromolecules to produce inhaleable dry powders

DATE-ISSUED: June 24, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Platz; Robert M.	Half Moon Bay	CA		
Patton; John S.	San Carlos	CA		
Foster; Linda	Sunnyvale	CA		
Eljamal; Mohammed	San Jose	CA		

US-CL-CURRENT: 424/489; 128/200.14, 424/45, 424/46, 514/958

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PDF | Draw Desc | Image

58. Document ID: US 6551578 B2

L2: Entry 58 of 102 File: USPT Apr 22, 2003

US-PAT-NO: 6551578
DOCUMENT-IDENTIFIER: US 6551578 B2

TITLE: Modulated release particles for aerosol delivery

DATE-ISSUED: April 22, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Adjei; Akwete L.	Bridgewater	NJ		
Zhu; Yaping	Highland Park	NJ		

US-CL-CURRENT: 424/45; 128/200.14, 514/1, 514/2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PDF | Draw Desc | Image

59. Document ID: US 6544497 B2

L2: Entry 59 of 102 File: USPT Apr 8, 2003

US-PAT-NO: 6544497
DOCUMENT-IDENTIFIER: US 6544497 B2

TITLE: Modulated release particles for aerosol delivery

DATE-ISSUED: April 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Zhu; Yaping	Highland Park	NJ		
Stefanos; Simon	Morris Plains	NJ		
Adjei; Akwete L.	Bridgewater	NJ		

US-CL-CURRENT: 424/45; 424/46, 424/489, 512/1, 514/2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PwwC | Draw Desc | Image

60. Document ID: US 6541606 B2

L2: Entry 60 of 102 File: USPT Apr 1, 2003

US-PAT-NO: 6541606
DOCUMENT-IDENTIFIER: US 6541606 B2

TITLE: Stabilized protein crystals formulations containing them and methods of making them

DATE-ISSUED: April 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Margolin; Alexey L.	Newton	MA		
Khalaf; Nazar K.	Worcester	MA		
St. Clair; Nancy L.	Ann Arbor	MI		
Rakestraw; Scott L.	Newark	DE		
Shenoy; Bhami C.	Woburn	MA		

US-CL-CURRENT: 530/350; 424/489, 424/501, 424/94.1, 424/94.2, 424/94.5, 424/94.6, 435/174, 435/178, 435/181, 435/183, 435/188, 435/39, 530/402, 530/403, 530/813, 530/815

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PwwC | Draw Desc | Image

61. Document ID: US 6509006 B1

L2: Entry 61 of 102 File: USPT Jan 21, 2003

US-PAT-NO: 6509006
DOCUMENT-IDENTIFIER: US 6509006 B1

TITLE: Devices compositions and methods for the pulmonary delivery of aerosolized medicaments

DATE-ISSUED: January 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Platz; Robert M.	Half Moon Bay	CA		
Patton; John S.	San Carlos	CA		
Foster; Linda	Sunnyvale	CA		
Eljamal; Mohammed	San Jose	CA		

US-CL-CURRENT: 424/46; 424/45, 424/489

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

62. Document ID: US 6485707 B2

L2: Entry 62 of 102 File: USPT Nov 26, 2002

US-PAT-NO: 6485707
DOCUMENT-IDENTIFIER: US 6485707 B2

TITLE: Modulated release particles for aerosol delivery

DATE-ISSUED: November 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Zhu; Yaping	Highland Park	NJ		
Adjei; Akwete L.	Bridgewater	NJ		

US-CL-CURRENT: 424/45; 512/1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

63. Document ID: US 6479457 B2

L2: Entry 63 of 102 File: USPT Nov 12, 2002

US-PAT-NO: 6479457
DOCUMENT-IDENTIFIER: US 6479457 B2

TITLE: Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides

DATE-ISSUED: November 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shalaby; Shalaby W.	Pendleton	SC		
Jackson; Steven A.	Holliston	MA		
Ignatious; Francis X.	Millville	MA		
Moreau; Jacques-Pierre	Upton	MA		
Russell; Ruth M.	Dublin			IE

US-CL-CURRENT: 514/9; 514/11

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

64. Document ID: US 6475468 B2

L2: Entry 64 of 102 File: USPT Nov 5, 2002

US-PAT-NO: 6475468
DOCUMENT-IDENTIFIER: US 6475468 B2

TITLE: Modulated release particles for aerosol delivery

DATE-ISSUED: November 5, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Zhu; Yaping	Highland Park	NJ		
Stefanos; Simon G.	Morris Plains	NJ		
Kline; Lukeysha	Toms River	NJ		
Adjei; Akwete L.	Bridgewater	NJ		

US-CL-CURRENT: 424/45; 128/200.14, 424/46, 514/3, 514/54

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PDMC | Draw Desc | Image

65. Document ID: US 6432449 B1

L2: Entry 65 of 102 File: USPT Aug 13, 2002

US-PAT-NO: 6432449
DOCUMENT-IDENTIFIER: US 6432449 B1
**** See image for Certificate of Correction ****

TITLE: Biodegradable sustained-release alginate gels

DATE-ISSUED: August 13, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Goldenberg; Merrill Seymour	Thousand Oaks	CA		
Gu; Jian Hua	Thousand Oaks	CA		

US-CL-CURRENT: 424/486; 424/426, 514/779, 514/909, 514/944

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PDMC | Draw Desc | Image

66. Document ID: US 6423344 B1

L2: Entry 66 of 102 File: USPT Jul 23, 2002

US-PAT-NO: 6423344
DOCUMENT-IDENTIFIER: US 6423344 B1

TITLE: Dispersible macromolecule compositions and methods for their preparation and use

DATE-ISSUED: July 23, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Platz; Robert M.	Half Moon Bay	CA		
Brewer; Thomas K.	Walnut Creek	CA		
Boardman; Terence D.	Palo Alto	CA		

US-CL-CURRENT: 424/491; 264/12, 264/5, 424/489, 424/497, 424/499, 514/2, 514/3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

67. Document ID: US 6420339 B1

L2: Entry 67 of 102 File: USPT Jul 16, 2002

US-PAT-NO: 6420339
DOCUMENT-IDENTIFIER: US 6420339 B1

TITLE: Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility

DATE-ISSUED: July 16, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gegg; Colin	Newbury Park	CA		
Kinstler; Olaf	Newbury Park	CA		

US-CL-CURRENT: 514/12; 514/2, 514/909, 530/350, 530/402

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

68. Document ID: US 6417164 B1

L2: Entry 68 of 102 File: USPT Jul 9, 2002

US-PAT-NO: 6417164
DOCUMENT-IDENTIFIER: US 6417164 B1

TITLE: Treatment of type II diabetes mellitus with amylin agonists

DATE-ISSUED: July 9, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kolterman; Orville G.	Poway	CA		
Thompson; Robert G.	San Diego	CA		
Mullane; John F.	Cardiff	CA		

US-CL-CURRENT: 514/12; 514/21, 514/4, 514/866

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

69. Document ID: US 6410511 B1

L2: Entry 69 of 102 File: USPT Jun 25, 2002

US-PAT-NO: 6410511
DOCUMENT-IDENTIFIER: US 6410511 B1

TITLE: Formulations for amylin agonist peptides

DATE-ISSUED: June 25, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
L'Italien; James	Del Mar	CA		
Musunuri; Shankar	Exton	PA		
Ruby; Kale	San Diego	CA		

US-CL-CURRENT: 514/12; 424/400, 514/2, 514/3, 514/4, 514/866, 514/884, 530/324

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PinIC | Draw Desc | Image

70. Document ID: US 6410508 B1

L2: Entry 70 of 102 File: USPT Jun 25, 2002

US-PAT-NO: 6410508
DOCUMENT-IDENTIFIER: US 6410508 B1
**** See image for Certificate of Correction ****

TITLE: Glucose-dependent insulinotropic peptide for use as an osteotropic hormone

DATE-ISSUED: June 25, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Isales; Carlos M.	Augusta	GA	30909	
Bollag; Roni J.	Martinez	GA	30907	
Rasmussen; Howard	Augusta	GA	30909	

US-CL-CURRENT: 514/2; 424/184.1, 424/198.1, 435/243, 435/325, 435/69.1, 514/12, 514/3, 530/303, 530/308

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PinIC | Draw Desc | Image

71. Document ID: US 6372258 B1

L2: Entry 71 of 102 File: USPT Apr 16, 2002

US-PAT-NO: 6372258
DOCUMENT-IDENTIFIER: US 6372258 B1

TITLE: Methods of spray-drying a drug and a hydrophobic amino acid

DATE-ISSUED: April 16, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Platz; Robert M.	Half Moon Bay	CA		
Patton; John S.	San Carlos	CA		
Foster; Linda	Sunnyvale	CA		
Eljamal; Mohammed	San Jose	CA		

US-CL-CURRENT: 424/489; 424/45, 424/46, 424/85.6, 514/2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

72. Document ID: US 6352982 B1

L2: Entry 72 of 102 File: USPT Mar 5, 2002

US-PAT-NO: 6352982
DOCUMENT-IDENTIFIER: US 6352982 B1

TITLE: 4,1-benzoxazepines, their analogues, and their use as somatostatin agonists

DATE-ISSUED: March 5, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mabuchi; Hiroshi	Nara			JP
Suzuki; Nobuhiro	Tsukuba			JP
Miki; Takashi	Osaka			JP

US-CL-CURRENT: 514/211.05; 540/490

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

73. Document ID: US 6217860 B1

L2: Entry 73 of 102 File: USPT Apr 17, 2001

US-PAT-NO: 6217860
DOCUMENT-IDENTIFIER: US 6217860 B1

TITLE: Gene therapy for solid tumors, papillomas and warts

DATE-ISSUED: April 17, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Woo; Savio L. C.	Houston	TX		
Chen; Shu-Hsia	Houston	TX		

US-CL-CURRENT: 424/93.2; 424/93.6, 435/320.1, 514/44

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

74. Document ID: US 6143718 A

L2: Entry 74 of 102 File: USPT Nov 7, 2000

US-PAT-NO: 6143718
DOCUMENT-IDENTIFIER: US 6143718 A

TITLE: Treatment of Type II diabetes mellutis with amylin agonists

DATE-ISSUED: November 7, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kolterman; Orville G.	Poway	CA		
Thompson; Robert G.	San Diego	CA		
Mullane; John F.	Cardiff	CA		

US-CL-CURRENT: 514/12; 514/21, 514/4

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PinIC | Draw Desc | Image

75. Document ID: US 6140475 A

L2: Entry 75 of 102 File: USPT Oct 31, 2000

US-PAT-NO: 6140475
DOCUMENT-IDENTIFIER: US 6140475 A
**** See image for Certificate of Correction ****

TITLE: Controlled dissolution crosslinked protein crystals

DATE-ISSUED: October 31, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Margolin; Alexey L.	Newton	MA		
Persichetti; Rose A.	Stow	MA		
St. Clair; Nancy L.	Durham	NC		
Khalaf; Nazer K.	Worcester	MA		

US-CL-CURRENT: 530/402; 424/94.1, 435/174, 435/188, 435/195, 435/198, 435/219, 435/262.5, 435/41, 436/518, 510/530, 530/810

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PinIC | Draw Desc | Image

76. Document ID: US 6136784 A

L2: Entry 76 of 102 File: USPT Oct 24, 2000

US-PAT-NO: 6136784
DOCUMENT-IDENTIFIER: US 6136784 A

TITLE: Amylin agonist pharmaceutical compositions containing insulin

DATE-ISSUED: October 24, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
L'Italien; James	Del Mar	CA		
Musunuri; Shankar	Exton	PA		
Ruby; Kale	San Diego	CA		
Kolterman; Orville	Poway	CA		

US-CL-CURRENT: 514/12; 514/21, 514/3, 514/4, 514/866

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

77. Document ID: US 6114304 A

L2: Entry 77 of 102 File: USPT Sep 5, 2000

US-PAT-NO: 6114304
DOCUMENT-IDENTIFIER: US 6114304 A

TITLE: Methods for regulating gastrointestinal motility

DATE-ISSUED: September 5, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kolterman; Orville G.	Poway	CA		
Young; Andrew A.	Alpine	CA		
Rink; Timothy J.	La Jolla	CA		
Brown; Kathleen Ann Keiting	Wake Forest	NC		

US-CL-CURRENT: 514/12; 514/3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

78. Document ID: US 6074845 A

L2: Entry 78 of 102 File: USPT Jun 13, 2000

US-PAT-NO: 6074845
DOCUMENT-IDENTIFIER: US 6074845 A

TITLE: Nucleic acid encoding a bovine calcitonin receptor-like receptor (BECRLR)

DATE-ISSUED: June 13, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Aiyar; Nambi V.	Berwyn	PA		
Disa; Jyoti	King of Prussia	PA		

US-CL-CURRENT: 435/69.1; 435/252.3, 435/254.11, 435/320.1, 435/325, 435/471, 435/71.1, 435/71.2, 530/350, 536/23.1, 536/23.5, 536/24.3, 536/24.31, 536/24.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

79. Document ID: US 6066624 A

L2: Entry 79 of 102 File: USPT May 23, 2000

US-PAT-NO: 6066624
DOCUMENT-IDENTIFIER: US 6066624 A

TITLE: Gene therapy for solid tumors using adenoviral vectors comprising suicide genes and cytokine genes

DATE-ISSUED: May 23, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Woo; Savio L. C.	Houston	TX		
Chen; Shu-Hsia	Houston	TX		

US-CL-CURRENT: 514/44; 424/93.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | DWIC | Drawing Desc | Image

80. Document ID: US 6051256 A

L2: Entry 80 of 102 File: USPT Apr 18, 2000

US-PAT-NO: 6051256
DOCUMENT-IDENTIFIER: US 6051256 A

TITLE: Dispersible macromolecule compositions and methods for their preparation and use

DATE-ISSUED: April 18, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Platz; Robert M.	Half Moon Bay	CA		
Brewer; Thomas K.	Walnut Creek	CA		
Boardman; Terence D.	Palo Alto	CA		

US-CL-CURRENT: 424/489; 424/46, 424/499, 514/2, 514/21, 514/3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | DWIC | Drawing Desc | Image

81. Document ID: US 6017885 A

L2: Entry 81 of 102 File: USPT Jan 25, 2000

US-PAT-NO: 6017885
DOCUMENT-IDENTIFIER: US 6017885 A

TITLE: IGF/IGFBP complex for promoting bone formation and for regulating bone remodeling

DATE-ISSUED: January 25, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bagi; Cedo Martin	Sunnyvale	CA		
Brommage; Robert	Santa Clara	CA		
Rosen; David M.	San Jose	CA		
Adams; Steven W.	Sunnyvale	CA		

US-CL-CURRENT: 514/12; 514/21, 514/3, 514/4, 530/303, 530/324, 530/399

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PwMC | Draw Desc | Image

82. Document ID: US 5998367 A

L2: Entry 82 of 102 File: USPT Dec 7, 1999

US-PAT-NO: 5998367
DOCUMENT-IDENTIFIER: US 5998367 A

TITLE: Pramlintide pro H-amylin salts and compositions

DATE-ISSUED: December 7, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gaeta; Laura S. L.	La Jolla	CA		
Jones; Howard	Poway	CA		
Albrecht; Elisabeth	San Diego	CA		

US-CL-CURRENT: 514/12; 514/24, 514/866, 530/324

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PwMC | Draw Desc | Image

83. Document ID: US 5922677 A

L2: Entry 83 of 102 File: USPT Jul 13, 1999

US-PAT-NO: 5922677
DOCUMENT-IDENTIFIER: US 5922677 A

TITLE: Therapeutic method and compounds of use therein

DATE-ISSUED: July 13, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Reid; Ian Reginald	Auckland			NZ
Cornish; Jillian	Auckland			NZ

US-CL-CURRENT: 514/12; 530/300, 530/324

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PwMC | Draw Desc | Image

84. Document ID: US 5843446 A

L2: Entry 84 of 102 File: USPT Dec 1, 1998

US-PAT-NO: 5843446
DOCUMENT-IDENTIFIER: US 5843446 A

TITLE: Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines

DATE-ISSUED: December 1, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ladd; Anna Efim	Brooklyn	NY		
Wang; Chang Yi	Cold Spring Harbor	NY		
Zamb; Timothy Joseph	Stony Brook	NY		

US-CL-CURRENT: 424/184.1; 424/185.1, 424/195.11, 424/811

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PinMC | Draw Desc | Image

85. Document ID: US 5834005 A

L2: Entry 85 of 102 File: USPT Nov 10, 1998

US-PAT-NO: 5834005
DOCUMENT-IDENTIFIER: US 5834005 A
**** See image for Certificate of Correction ****

TITLE: Bioartificial devices and cellular matrices therefor

DATE-ISSUED: November 10, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Usala; Anton-Lewis	Winterville	NC		

US-CL-CURRENT: 424/424; 435/182, 514/772.3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PinMC | Draw Desc | Image

86. Document ID: US 5830492 A

L2: Entry 86 of 102 File: USPT Nov 3, 1998

US-PAT-NO: 5830492
DOCUMENT-IDENTIFIER: US 5830492 A
**** See image for Certificate of Correction ****

TITLE: Bioartificial devices and cellular matrices therefor

DATE-ISSUED: November 3, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Usala; Anton-Lewis	Winterville	NC		

US-CL-CURRENT: 424/424; 435/182, 514/772.3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PinMC | Draw Desc | Image

87. Document ID: US 5824331 A

L2: Entry 87 of 102 File: USPT Oct 20, 1998

US-PAT-NO: 5824331
DOCUMENT-IDENTIFIER: US 5824331 A

TITLE: Bioartificial devices and cellular matrices therefor

DATE-ISSUED: October 20, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Usala; Anton-Lewis	Winterville	NC		

US-CL-CURRENT: 424/424; 435/182, 514/772.3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PwdC | Draw Desc | Image

88. Document ID: US 5821221 A

L2: Entry 88 of 102 File: USPT Oct 13, 1998

US-PAT-NO: 5821221
DOCUMENT-IDENTIFIER: US 5821221 A

TITLE: Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides

DATE-ISSUED: October 13, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shalaby; Shalaby W.	Anderson	SC		
Jackson; Steven A.	Holliston	MA		
Ignatious; Francis	Milford	MA		
Moreau; Jacques-Pierre	Upton	MA		

US-CL-CURRENT: 514/9; 514/11

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PwdC | Draw Desc | Image

89. Document ID: US 5795861 A

L2: Entry 89 of 102 File: USPT Aug 18, 1998

US-PAT-NO: 5795861
DOCUMENT-IDENTIFIER: US 5795861 A

TITLE: Methods for regulating gastrointestinal motility

DATE-ISSUED: August 18, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kolterman; Orville G.	Poway	CA		
Rink; Timothy J.	La Jolla	CA		

US-CL-CURRENT: 514/12; 514/11, 514/13, 514/866, 530/307, 530/327

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PwMC | Draw Desc | Image

90. Document ID: US 5759551 A

L2: Entry 90 of 102 File: USPT Jun 2, 1998

US-PAT-NO: 5759551
DOCUMENT-IDENTIFIER: US 5759551 A

TITLE: Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines

DATE-ISSUED: June 2, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ladd; Anna Efim	Brooklyn	NY		
Wang; Chang Yi	Cold Spring Harbor	NY		
Zamb; Timothy Joseph	Stony Brook	NY		

US-CL-CURRENT: 424/198.1; 424/185.1, 424/227.1, 514/841, 514/843

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PwMC | Draw Desc | Image

91. Document ID: US 5686411 A

L2: Entry 91 of 102 File: USPT Nov 11, 1997

US-PAT-NO: 5686411
DOCUMENT-IDENTIFIER: US 5686411 A

TITLE: Amylin agonist peptides and uses therefor

DATE-ISSUED: November 11, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gaeta; Laura S. L.	Foster City	CA		
Jones; Howard	Poway	CA		
Albrecht; Elisabeth	San Diego	CA		

US-CL-CURRENT: 514/12; 514/2, 514/4, 514/866, 530/324

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PwMC | Draw Desc | Image

92. Document ID: US 5677279 A

L2: Entry 92 of 102 File: USPT Oct 14, 1997

US-PAT-NO: 5677279
DOCUMENT-IDENTIFIER: US 5677279 A

TITLE: Methods and compositions for treating pain with amylin or agonists thereof

DATE-ISSUED: October 14, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Young; Andrew A.	San Diego	CA		

US-CL-CURRENT: 514/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PDF | Draw Desc | Image

93. Document ID: US 5665702 A

L2: Entry 93 of 102 File: USPT Sep 9, 1997

US-PAT-NO: 5665702
DOCUMENT-IDENTIFIER: US 5665702 A

TITLE: Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides

DATE-ISSUED: September 9, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shalaby; Shalaby W.	Anderson	SC		
Jackson; Steven A.	Holliston	MA		
Ignatious; Francis	Milford	MA		
Moreau; Jacques-Pierre	Upton	MA		

US-CL-CURRENT: 514/9; 514/11

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PDF | Draw Desc | Image

94. Document ID: US 5631236 A

L2: Entry 94 of 102 File: USPT May 20, 1997

US-PAT-NO: 5631236
DOCUMENT-IDENTIFIER: US 5631236 A

TITLE: Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk

DATE-ISSUED: May 20, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Woo; Savio L. C.	Houston	TX		
Chen; Shu-Hsia	Houston	TX		

US-CL-CURRENT: 514/44; 424/93.6, 435/320.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PDF | Draw Desc | Image

95. Document ID: US 5625032 A

L2: Entry 95 of 102 File: USPT Apr 29, 1997

US-PAT-NO: 5625032
DOCUMENT-IDENTIFIER: US 5625032 A

TITLE: Selective amylin antagonist peptides and uses therefor

DATE-ISSUED: April 29, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gaeta; Lori	Olivenhain	CA		
Beaumont; Kevin	San Diego	CA		
Prickett; Kathryn	San Diego	CA		

US-CL-CURRENT: 530/324; 530/325, 530/326

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

96. Document ID: US 5607691 A

L2: Entry 96 of 102 File: USPT Mar 4, 1997

US-PAT-NO: 5607691
DOCUMENT-IDENTIFIER: US 5607691 A

TITLE: Compositions and methods for enhanced drug delivery

DATE-ISSUED: March 4, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hale; Ron L.	Woodside	CA		
Lu; Amy	Los Altos	CA		
Solas; Dennis	San Francisco	CA		
Selick; Harold E.	Belmont	CA		
Oldenburg; Kevin R.	Fremont	CA		
Zaffaroni; Alejandro C.	Atherton	CA		

US-CL-CURRENT: 424/449; 514/1, 514/169, 514/183, 514/2, 514/26, 514/553, 514/556, 604/20

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

97. Document ID: US 5516651 A

L2: Entry 97 of 102 File: USPT May 14, 1996

US-PAT-NO: 5516651
DOCUMENT-IDENTIFIER: US 5516651 A
**** See image for Certificate of Correction ****

TITLE: Nucleic acids encoding calcitonin receptor and uses thereof

DATE-ISSUED: May 14, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Goldring; Steven R.	Auburndale	MA		
Gorn; Alan H.	Boston	MA		
Lin; Herb Y.	Cambridge	MA		

US-CL-CURRENT: 435/69.1; 435/320.1, 435/365, 435/6, 536/23.1, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | DWIC | Draw Desc | Image

98. Document ID: US 5405831 A

L2: Entry 98 of 102 File: USPT Apr 11, 1995

US-PAT-NO: 5405831
DOCUMENT-IDENTIFIER: US 5405831 A

TITLE: Treatment of bone disorders

DATE-ISSUED: April 11, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
MacIntyre; Iain	Heathfield			GB2

US-CL-CURRENT: 514/4; 514/12, 530/303, 530/307, 530/324

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | DWIC | Draw Desc | Image

99. Document ID: US 5376638 A

L2: Entry 99 of 102 File: USPT Dec 27, 1994

US-PAT-NO: 5376638
DOCUMENT-IDENTIFIER: US 5376638 A

TITLE: Methods for treating renin-related disorders with amylin antagonists

DATE-ISSUED: December 27, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Young; Andrew A.	San Diego	CA		
Rink; Timothy J.	La Jolla	CA		

US-CL-CURRENT: 514/12; 514/11, 514/13

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | DWIC | Draw Desc | Image

100. Document ID: US 5264372 A

L2: Entry 100 of 102 File: USPT Nov 23, 1993

US-PAT-NO: 5264372
DOCUMENT-IDENTIFIER: US 5264372 A

TITLE: Receptor-based screening methods for amylin agonists and antagonists

DATE-ISSUED: November 23, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Beaumont; Kevin	San Diego	CA		
Rink; Timothy J.	San Diego	CA		

US-CL-CURRENT: 436/504; 436/501, 436/503

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PinIC | Draw Desc | Image

101. Document ID: WO 9916406 A2 JP 2001524454 W AU 9893690 A EP 1027027 A2

L2: Entry 101 of 102 File: DWPI Apr 8, 1999

DERWENT-ACC-NO: 1999-277029
DERWENT-WEEK: 200203
COPYRIGHT 2003 DERWENT INFORMATION LTD
TITLE: Treating patient to stimulate chondrocyte proliferation in vivo comprising administration of amylin, adrenomedullin or ligand growth to stimulate receptor useful for cartilage/bone repair

INVENTOR: CORNISH, J; REID, I R

PRIORITY-DATA: 1997NZ-0328853 (September 26, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9916406 A2	April 8, 1999	E	025	A61K000/00
JP 2001524454 W	December 4, 2001		029	A61K045/00
AU 9893690 A	April 23, 1999		000	
EP 1027027 A2	August 16, 2000	E	000	A61K006/00

INT-CL (IPC): A61 K 0/00; A61 K 6/00; A61 K 38/00; A61 K 45/00; A61 P 19/08; A61 P 43/00

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | PinIC | Draw Desc | Image

102. Document ID: EP 408284 A SG 46382 A1 WO 9100710 A DK 9100401 A JP 04500691 W CA 2020752 A EP 408284 A3 IE 62625 B US 5405831 A EP 408284 B1 DE 69026986 E ES 2088971 T3 CA 2020752 C

L2: Entry 102 of 102 File: DWPI Jan 16, 1991

DERWENT-ACC-NO: 1991-016477
DERWENT-WEEK: 199821
COPYRIGHT 2003 DERWENT INFORMATION LTD
TITLE: Use of amylin or variants and agonists - for treating bone disorders e.g. osteoporosis, pagets disease or hypocalcaemic

INVENTOR: MACINTYRE, I

PRIORITY-DATA: 1989GB-0015712 (July 8, 1989)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 408284 A	January 16, 1991		008	
SG 46382 A1	February 20, 1998		000	A61K037/02
WO 9100710 A	January 24, 1991		000	
DK 9100401 A	March 7, 1991		000	
JP 04500691 W	February 6, 1992		009	
CA 2020752 A	January 10, 1992		000	
EP 408284 A3	January 2, 1992		008	
IE 62625 B	February 22, 1995		000	A61K037/02
US 5405831 A	April 11, 1995		008	A61K037/02
EP 408284 B1	May 15, 1996	E	011	A61K038/00
DE 69026986 E	June 20, 1996		000	A61K038/00
ES 2088971 T3	October 1, 1996		000	A61K038/00
CA 2020752 C	December 24, 1996		000	A61K038/22

INT-CL (IPC): A61B 19/00; A61K 37/02; A61K 37/24; A61K 37/30; A61K 38/00; A61K 38/08; A61K 38/22; A61K 38/28; C07K 7/08 ; G01N 33/48; G01N 33/68

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | OMC | Draw Desc | Clip Img | Image

Generate Collection | Print

Term	Documents
TREAT$	0
TREAT	578631
TREATA	1
TREATABIL	1
TREATABILIT	1
TREATABILITIES	2
TREATABILITY	623
TREATABILITYOF	1
TREATABILITY]	2
TREATABLE	8216
(L1 AND TREAT$ AND ADMINIST$).USPT,PGPB,EPAB,DWPI,TDBD.	102

There are more results than shown above. Click here to view the entire set.

Display Format: | Change Format

Previous Page Next Page

1: Cornish J, Callon KE, Cooper GJ, Reid IR. Related Articles, Links

Amylin stimulates osteoblast proliferation and increases mineralized bone volume in adult mice.
Biochem Biophys Res Commun. 1995 Feb 6;207(1):133-9.
PMID: 7857256 [PubMed - indexed for MEDLINE]

2: Cornish J, Callon KE, Coy DH, Jiang NY, Xiao L, Cooper GJ, Reid IR. Related Articles, Links

Adrenomedullin is a potent stimulator of osteoblastic activity in vitro and in vivo.
Am J Physiol. 1997 Dec;273(6 Pt 1):E1113-20.
PMID: 9435526 [PubMed - indexed for MEDLINE]

3: Cornish J, Callon KE, Lin CQ, Xiao CL, Mulvey TB, Coy DH, Cooper GJ, Reid IR. Related Articles, Links

Dissociation of the effects of amylin on osteoblast proliferation and bone resorption.
Am J Physiol. 1998 May;274(5 Pt 1):E827-33.
PMID: 9612240 [PubMed - indexed for MEDLINE]

4: Cornish J, Callon KE, King AR, Cooper GJ, Reid IR. Related Articles, Links

Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice.
Am J Physiol. 1998 Oct;275(4 Pt 1):E694-9.
PMID: 9755090 [PubMed - indexed for MEDLINE]

5: Cornish J, Callon KE, Gasser JA, Bava U, Gardiner EM, Coy DH, Cooper GJ, Reid IR. Related Articles, Links

Systemic administration of a novel octapeptide, amylin-(1---8), increases bone volume in male mice.
Am J Physiol Endocrinol Metab. 2000 Oct;279(4):E730-5.
PMID: 11001752 [PubMed - indexed for MEDLINE]

6: Villa I, Melzi R, Pagani F, Ravasi F, Rubinacci A, Guidobono F. Related Articles, Links

Effects of calcitonin gene-related peptide and amylin on human osteoblast-like cells proliferation.
Eur J Pharmacol. 2000 Dec 15;409(3):273-8.
PMID: 11108821 [PubMed - indexed for MEDLINE]

7: Cornish J, Callon KE, Lin CQ, Xiao CL, Gamble GD, Cooper GJ, Reid IR. Related Articles, Links

Comparison of the effects of calcitonin gene-related peptide and amylin on osteoblasts.
J Bone Miner Res. 1999 Aug;14(8):1302-9.
PMID: 10457262 [PubMed - indexed for MEDLINE]

8: Cornish J, Callon KE, Reid IR. Related Articles, Links

Insulin increases histomorphometric indices of bone formation In vivo.

Calcif Tissue Int. 1996 Dec;59(6):492-5.
PMID: 8939777 [PubMed - indexed for MEDLINE]

9: Datta HK, Zaidi M, Wimalawansa SJ, Ghatei MA, Beacham JL, Bloom SR, MacIntyre I. Related Articles, Links

In vivo and in vitro effects of amylin and amylin-amide on calcium metabolism in the rat and rabbit.
Biochem Biophys Res Commun. 1989 Jul 31;162(2):876-81.
PMID: 2787991 [PubMed - indexed for MEDLINE]

10: Cornish J, Naot D. Related Articles, Links

Amylin and adrenomedullin: novel regulators of bone growth.
Curr Pharm Des. 2002;8(23):2009-21. Review.
PMID: 12171515 [PubMed - indexed for MEDLINE]

11: Cornish J, Callon KE, Lin CQ, Xiao CL, Mulvey TB, Cooper GJ, Reid IR. Related Articles, Links

Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytes.
Am J Physiol. 1999 Nov;277(5 Pt 1):E779-83.
PMID: 10567002 [PubMed - indexed for MEDLINE]

12: Tamura T, Miyaura C, Owan I, Suda T. Related Articles, Links

Mechanism of action of amylin in bone.
J Cell Physiol. 1992 Oct;153(1):6-14.
PMID: 1325980 [PubMed - indexed for MEDLINE]

13: Villa I, Dal Fiume C, Maestroni A, Rubinacci A, Ravasi F, Guidobono F. Related Articles, Links

Human osteoblast-like cell proliferation induced by calcitonin-related peptides involves PKC activity.
Am J Physiol Endocrinol Metab. 2003 Mar;284(3):E627-33. Epub 2002 Nov 12.
PMID: 12556355 [PubMed - indexed for MEDLINE]

14: Alam AS, Moonga BS, Bevis PJ, Huang CL, Zaidi M. Related Articles, Links

Amylin inhibits bone resorption by a direct effect on the motility of rat osteoclasts.
Exp Physiol. 1993 Mar;78(2):183-96.
PMID: 8385961 [PubMed - indexed for MEDLINE]

15: Cornish J, Callon KE, Bava U, Kamona SA, Cooper GJ, Reid IR. Related Articles, Links

Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development.
Bone. 2001 Aug;29(2):162-8.
PMID: 11502478 [PubMed - indexed for MEDLINE]

16: Villa I, Rubinacci A, Ravasi F, Ferrara AF, Guidobono F. Related Articles, Links

Effects of amylin on human osteoblast-like cells.
Peptides. 1997;18(4):537-40.
PMID: 9210172 [PubMed - indexed for MEDLINE]

17: Notoya K, Yoshida K, Tsukuda R, Taketomi S. Related Articles, Links

Effect of ipriflavone on expression of markers characteristic of the osteoblast phenotype in rat bone marrow stromal cell culture.
J Bone Miner Res. 1994 Mar;9(3):395-400.
PMID: 8191934 [PubMed - indexed for MEDLINE]

18: Pietschmann P, Farsoudi KH, Hoffmann O, Klaushofer K, Horandner H, Peterlik Related Articles, Links

M.

Inhibitory effect of amylin on basal and parathyroid hormone-stimulated bone resorption in cultured neonatal mouse calvaria.
Bone. 1993 Mar-Apr;14(2):167-72.
PMID: 8334035 [PubMed - indexed for MEDLINE]

19: Cornish J, Callon KE, Nicholson GC, Reid IR. Related Articles, Links

Parathyroid hormone-related protein-(107-139) inhibits bone resorption in vivo.
Endocrinology. 1997 Mar;138(3):1299-304.
PMID: 9048639 [PubMed - indexed for MEDLINE]

20: Mackie EJ, Abraham LA, Taylor SL, Tucker RP, Murphy LI. Related Articles, Links

Regulation of tenascin-C expression in bone cells by transforming growth factor-beta.
Bone. 1998 Apr;22(4):301-7.
PMID: 9556128 [PubMed - indexed for MEDLINE]

Display Summary Show: 20 Sort Send to Text
Items 1-20 of 204 Page 1 of 11 Next

Items 21-40 of 204 Previous Page 2 of 11 Next

21: Stashenko P, Dewhirst FE, Rooney ML, Desjardins LA, Heeley JD. Related Articles, Links

Interleukin-1 beta is a potent inhibitor of bone formation in vitro.
J Bone Miner Res. 1987 Dec;2(6):559-65.
PMID: 3502684 [PubMed - indexed for MEDLINE]

22: Hsieh SC, Graves DT. Related Articles, Links

Pulse application of platelet-derived growth factor enhances formation of a mineralizing matrix while continuous application is inhibitory.
J Cell Biochem. 1998 May 1;69(2):169-80.
PMID: 9548564 [PubMed - indexed for MEDLINE]

23: Young AA, Rink TJ, Wang MW. Related Articles, Links

Dose response characteristics for the hyperglycemic, hyperlactemic, hypotensive and hypocalcemic actions of amylin and calcitonin gene-related peptide-I (CGRP alpha) in the fasted, anaesthetized rat.
Life Sci. 1993;52(21):1717-26.
PMID: 8502117 [PubMed - indexed for MEDLINE]

24: Zerath E, Holy X, Noel B, Malouvier A, Hott M, Marie PJ. Related Articles, Links

Effects of BMP-2 on osteoblastic cells and on skeletal growth and bone formation in unloaded rats.
Growth Horm IGF Res. 1998 Apr;8(2):141-9.
PMID: 10987681 [PubMed - indexed for MEDLINE]

25: Ghatei MA, Datta HK, Zaidi M, Bretherton-Watt D, Wimalawansa SJ, MacIntyre I, Bloom SR. Related Articles, Links

Amylin and amylin-amide lack an acute effect on blood glucose and insulin.
J Endocrinol. 1990 Feb;124(2):R9-11.
PMID: 2179452 [PubMed - indexed for MEDLINE]

26: Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, Spelsberg TC. Related Articles, Links

Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts.
Cancer Res. 2000 Nov 1;60(21):6001-7.
PMID: 11085520 [PubMed - indexed for MEDLINE]

27: Silvestre RA, Salas M, Rodriguez-Gallardo J, Garcia-Hermida O, Fontela T, Marco J. Related Articles, Links

Effect of (8-32) salmon calcitonin, an amylin antagonist, on insulin, glucagon and somatostatin release: study in the perfused pancreas of the rat.
Br J Pharmacol. 1996 Jan;117(2):347-50.
PMID: 8789389 [PubMed - indexed for MEDLINE]

28: Chow JW, Lean JM, Chambers TJ. Related Articles, Links

17 beta-estradiol stimulates cancellous bone formation in female rats.
Endocrinology. 1992 May;130(5):3025-32.
PMID: 1572310 [PubMed - indexed for MEDLINE]

29: Burns DM, Howard GA, Roos BA. Related Articles, Links

An assessment of the anabolic skeletal actions of the common-region peptides derived from the CGRP and calcitonin prohormones.
Ann N Y Acad Sci. 1992 Jun 30;657:50-62. No abstract available.
PMID: 1637109 [PubMed - indexed for MEDLINE]

30: Panagakos FS. Related Articles, Links

Insulin-like growth factors-I and -II stimulate chemotaxis of osteoblasts isolated from fetal rat calvaria.
Biochimie. 1993;75(11):991-4.
PMID: 8123707 [PubMed - indexed for MEDLINE]

31: Johnson RB, Henderson JS. Related Articles, Links

Enhancement by sodium orthovanadate of the formation and mineralization of bone nodules by chick osteoblasts in vitro.
Arch Oral Biol. 1997 Apr;42(4):271-6.
PMID: 9222445 [PubMed - indexed for MEDLINE]

32: Lerner UH, Johansson L, Ranjso M, Rosenquist JB, Reinholt FP, Grubb A. Related Articles, Links

Cystatin C, and inhibitor of bone resorption produced by osteoblasts.
Acta Physiol Scand. 1997 Sep;161(1):81-92. Erratum in: Acta Physiol Scand 1998 Feb;162(2):175.
PMID: 9381954 [PubMed - indexed for MEDLINE]

33: Kim CH, Kang BS, Lee TK, Park WH, Kim JK, Park YG, Kim HM, Lee YC. Related Articles, Links

IL-1beta regulates cellular proliferation, prostaglandin E2 synthesis, plasminogen activator activity, osteocalcin production, and bone resorptive activity of the mouse calvarial bone cells.
Immunopharmacol Immunotoxicol. 2002 Aug;24(3):395-407.
PMID: 12375736 [PubMed - indexed for MEDLINE]

34: Pittner RA, Wolfe-Lopez D, Young AA, Beaumont K. Related Articles, Links

Different pharmacological characteristics in L6 and C2C12 muscle cells and intact rat skeletal muscle for amylin, CGRP and calcitonin.
Br J Pharmacol. 1996 Mar;117(5):847-52.
PMID: 8851500 [PubMed - indexed for MEDLINE]

35: Farley JR, Hall SL, Tarbaux NM. Related Articles, Links

Calcitonin (but not calcitonin gene-related peptide) increases mouse bone cell proliferation in a dose-dependent manner, and increases mouse bone formation, alone and in combination with fluoride.
Calcif Tissue Int. 1989 Oct;45(4):214-21.
PMID: 2509008 [PubMed - indexed for MEDLINE]

36: Silvestre RA, Salas M, Degano P, Peiro E, Marco J. Related Articles, Links

Reversal of the inhibitory effects of calcitonin gene-related peptide (CGRP) and amylin on insulin secretion by the 8-37 fragment of human CGRP.
Biochem Pharmacol. 1993 Jun 9;45(11):2343-7.
PMID: 8517876 [PubMed - indexed for MEDLINE]

37: Zaidi M, Fuller K, Bevis PJ, GainesDas RE, Chambers TJ, MacIntyre I. Related Articles, Links

Calcitonin gene-related peptide inhibits osteoclastic bone resorption: a comparative study.
Calcif Tissue Int. 1987 Mar;40(3):149-54.
PMID: 3105845 [PubMed - indexed for MEDLINE]

38: Rao LG, Liu LJ, Murray TM, McDermott E. Related Articles, Links

17Beta-estradiol stimulates mineralized bone nodule formation when added intermittently to SaOS-2 cells.
Drug Metabol Drug Interact. 2001;18(2):149-58.
PMID: 11460877 [PubMed - indexed for MEDLINE]

39: Wimalawansa SJ, Gunasekera RD, Datta HK. Related Articles, Links

Hypocalcemic actions of amylin amide in humans.
J Bone Miner Res. 1992 Sep;7(9):1113-6.
PMID: 1414504 [PubMed - indexed for MEDLINE]

40: Pittner R A, Albrandt K, Beaumont K, Gaeta LS, Koda JE, Moore CX, Rittenhouse J, Rink TJ. Related Articles, Links

Molecular physiology of amylin.
J Cell Biochem. 1994;55 Suppl:19-28. Review.
PMID: 7929615 [PubMed - indexed for MEDLINE]

Display Summary Show: 20 Sort Send to Text

Items 21-40 of 204 Previous Page 2 of 11 Next

41: Hiruma Y, Inoue A, Shiohama A, Otsuka E, Hirose S, Yamaguchi A, Hagiwara H. Related Articles, Links

Endothelins inhibit mineralization of rat calvarial osteoblast-like cells.
J Cardiovasc Pharmacol. 1998;31 Suppl 1:S521-3.
PMID: 9595531 [PubMed - indexed for MEDLINE]

42: Cornish J, Callon KE, Bava U, Coy DH, Mulvey TB, Murray MA, Cooper GJ, Cooper GJ, Reid IR. Related Articles, Links

Systemic administration of adrenomedullin(27-52) increases bone volume and strength in male mice.
J Endocrinol. 2001 Jul;170(1):251-7.
PMID: 11431158 [PubMed - indexed for MEDLINE]

43: Cornish J, Callon KE, Lin C, Xiao C, Moseley JM, Reid IR. Related Articles, Links

Stimulation of osteoblast proliferation by C-terminal fragments of parathyroid hormone-related protein.
J Bone Miner Res. 1999 Jun;14(6):915-22.
PMID: 10352099 [PubMed - indexed for MEDLINE]

44: Vignery A, McCarthy TL. Related Articles, Links

The neuropeptide calcitonin gene-related peptide stimulates insulin-like growth factor I production by primary fetal rat osteoblasts.
Bone. 1996 Apr;18(4):331-5.
PMID: 8726390 [PubMed - indexed for MEDLINE]

45: Bouali SM, Wimalawansa SJ, Jolicoeur FB. Related Articles, Links

In vivo central actions of rat amylin.
Regul Pept. 1995 Apr 14;56(2-3):167-74.
PMID: 7652192 [PubMed - indexed for MEDLINE]

46: Kato H, Matsuo R, Komiyama O, Tanaka T, Inazu M, Kitagawa H, Yoneda T. Related Articles, Links

Decreased mitogenic and osteogenic responsiveness of calvarial osteoblasts isolated from aged rats to basic fibroblast growth factor.
Gerontology. 1995;41 Suppl 1:20-7.
PMID: 8537016 [PubMed - indexed for MEDLINE]

47: Visconti LA, Yen EH, Johnson RB. Related Articles, Links

Effects of sodium acetate on rat bone-nodule formation and mineralization in vitro.
Arch Oral Biol. 1998 Sep;43(9):729-33.
PMID: 9783827 [PubMed - indexed for MEDLINE]

48: Huang Y, Fischer JE, Balasubramaniam A. Related Articles, Links

Amylin mobilizes [Ca2+]i and stimulates the release of pancreatic digestive enzymes

from rat acinar AR42J cells: evidence for an exclusive receptor system of amylin.
Peptides. 1996;17(3):497-502.
PMID: 8735978 [PubMed - indexed for MEDLINE]

49: Lutz TA, Rossi R, Althaus J, Del Prete E, Scharrer E. Related Articles, Links

Amylin reduces food intake more potently than calcitonin gene-related peptide (CGRP) when injected into the lateral brain ventricle in rats.
Peptides. 1998;19(9):1533-40.
PMID: 9864060 [PubMed - indexed for MEDLINE]

50: Leighton B, Cooper GJ. Related Articles, Links

Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro.
Nature. 1988 Oct 13;335(6191):632-5.
PMID: 3050530 [PubMed - indexed for MEDLINE]

51: Mullan PB, Lax AJ. Related Articles, Links

Pasteurella multocida toxin stimulates bone resorption by osteoclasts via interaction with osteoblasts.
Calcif Tissue Int. 1998 Oct;63(4):340-5.
PMID: 9744994 [PubMed - indexed for MEDLINE]

52: Suzuki Y, Morita I, Yamane Y, Murota S. Related Articles, Links

Preventive effect of zinc against cadmium-induced bone resorption.
Toxicology. 1990 May 14;62(1):27-34.
PMID: 2343456 [PubMed - indexed for MEDLINE]

53: Molina JM, Cooper GJ, Leighton B, Olefsky JM. Related Articles, Links

Induction of insulin resistance in vivo by amylin and calcitonin gene-related peptide.
Diabetes. 1990 Feb;39(2):260-5.
PMID: 2227135 [PubMed - indexed for MEDLINE]

54: Henderson JS, Johnson RB. Related Articles, Links

The effects of smokeless tobacco extract on bone nodule formation and mineralization by chick osteoblasts in vitro.
Arch Oral Biol. 1995 Jul;40(7):615-21.
PMID: 7575233 [PubMed - indexed for MEDLINE]

55: Giuliani N, Pedrazzoni M, Negri G, Passeri G, Impicciatore M, Girasole G. Related Articles, Links

Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo.
Bone. 1998 May;22(5):455-61.
PMID: 9600778 [PubMed - indexed for MEDLINE]

56: Bronsky J, Chada M, Kotaska K, Prusa R. Related Articles, Links

[Amylin--its physiological role in humans]
Cesk Fysiol. 2002 Dec;51(4):176-80. Review. Czech.
PMID: 12608111 [PubMed - indexed for MEDLINE]

57: Vine W, Beaumont K, Gedulin B, Pittner R, Moore CX, Rink TJ, Young AA. Related Articles, Links

Comparison of the in vitro and in vivo pharmacology of adrenomedullin, calcitonin gene-related peptide and amylin in rats.
Eur J Pharmacol. 1996 Oct 24;314(1-2):115-21.

PMID: 8957226 [PubMed - indexed for MEDLINE]

58: Alam AS, Bax CM, Shankar VS, Bax BE, Bevis PJ, Huang CL, Moonga BS, Pazianas M, Zaidi M. Related Articles, Links

Further studies on the mode of action of calcitonin on isolated rat osteoclasts: pharmacological evidence for a second site mediating intracellular Ca2+ mobilization and cell retraction.
J Endocrinol. 1993 Jan;136(1):7-15.
PMID: 8429278 [PubMed - indexed for MEDLINE]

59: Lau KH, Wang SP, Linkhart TA, Demarest KT, Baylink DJ. Related Articles, Links

Picomolar norethindrone in vitro stimulates the cell proliferation and activity of a human osteosarcoma cell line and increases bone collagen synthesis without an effect on bone resorption.
J Bone Miner Res. 1994 May;9(5):695-703.
PMID: 8053399 [PubMed - indexed for MEDLINE]

60: Miller SC, Jee WS. Related Articles, Links

The comparative effects of dichloromethylene diphosphonate (C12MDP) and ethane-1-hydroxy-1,1-diphosphonate (EHDP) on growth and modeling of the rat tibia.
Calcif Tissue Res. 1977 Oct 20;23(3):207-14.
PMID: 143335 [PubMed - indexed for MEDLINE]

Display Summary Show: 20 Sort Send to Text

Items 41-60 of 204 Previous Page 3 of 11 Next

1: Regul Pept. 1995 Apr 14;56(2-3):167-74.

In vivo central actions of rat amylin.

Bouali SM, Wimalawansa SJ, Jolicoeur FB.

Department of Psychiatry, Faculty of Medicine, University of Sherbrooke, Quebec, Canada.

The purpose of the present study was to examine and compare the profile of neurobehavioral effects of rat amylin (r-amylin) and rat calcitonin gene-related peptide (rCGRP), two peptides having a 50% structural homology. The effects of synthetic r-amylin and rCGRP administered in several doses (0.312-80.0 micrograms) into the lateral cerebro-ventricle of rats on spontaneous activity, muscular tone, body temperature, nociception, food intake as well as their potential for inducing catalepsy, were investigated. Intraventricular administration of r-amylin or rCGRP significantly reduced spontaneous motor activity and markedly increased body temperature of animals in a dose-dependent related fashion. rCGRP produced a significant increase in muscular tone and induced cataleptic effect in animals, but r-amylin had no effect on these variables. Furthermore, neither r-amylin nor rCGRP were able to induce any significant effect on nociceptive response time of animals in the tail immersion test even with doses as large as 80.0 micrograms. Finally, the two peptides did not affect ad libitum food intake, but significantly reduced food consumption in 22 h food-deprived animals. Together, the results of the present study suggest that amylin may be involved in a diversity of neurophysiological processes but displays a different profile of neurobehavioral effects to that of CGRP which may involve different receptors.

PMID: 7652192 [PubMed - indexed for MEDLINE]

1: Peptides. 1997;18(4):537-40.

Effects of amylin on human osteoblast-like cells.

Villa I, Rubinacci A, Ravasi F, Ferrara AF, Guidobono F.

Bone Metabolic Unit, Scientific Institute H San Raffaele, Milano, Italy.

Amylin has been reported to have bone-conserving effects. In the present study we evaluated the possible activity of the peptide on human osteoblast-like (hOB) cells in primary culture. Amylin between 10(-9) and 10(-6) M, dose-dependently stimulated cell proliferation with a maximal effect (200%) at 10(-6) M. In addition, amylin increased osteocalcin production when hOB cells were exposed to 1,25(OH)2D3 (10(-8)M) but there was a nonsignificant upward trend on alkaline phosphatase activity. The present results suggest that amylin could be included among the group of peptides endowed with osteogenic activity.

PMID: 9210172 [PubMed - indexed for MEDLINE]

1: Biochem Biophys Res Commun. 1995 Feb 6;207(1):133-9.

Related Articles, Links

Amylin stimulates osteoblast proliferation and increases mineralized bone volume in adult mice.

Cornish J, Callon KE, Cooper GJ, Reid IR.

Department of Medicine, University of Auckland, New Zealand.

Amylin, a 37-amino-acid peptide co-secreted with insulin from the beta-cells of the pancreatic islets, has previously been demonstrated to inhibit bone resorption in vitro. However, its effects on bone formation and bone mass have not been assessed. We report that periphysiological concentrations of amylin stimulate proliferation of fetal rat osteoblasts in vitro. When amylin is injected daily for 5 days over the calvariae of adult mice in vivo, there are substantial increases in histomorphometric indices of bone formation, a reduction in bone resorption, and a significant increase in mineralized bone area. Equimolar doses of calcitonin in this in vivo model produced an inhibition of bone resorption but no significant effect on bone area. These findings support a role for amylin as a physiological regulator of bone and suggest that it should also be evaluated as a potential treatment for osteoporosis.

PMID: 7857256 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

NCBI PubMed National Library of Medicine NLM

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Privacy Policy

Limits: **Publication Date to 1997**

Display Summary Show: 20 Sort Send to Text

Items 1-2 of 2

One page.

1: Cornish J, Callon KE, Cooper GJ, Reid IR. Related Articles, Links

Amylin stimulates osteoblast proliferation and increases mineralized bone volume in adult mice.
Biochem Biophys Res Commun. 1995 Feb 6;207(1):133-9.
PMID: 7857256 [PubMed - indexed for MEDLINE]

2: Romero DF, Bryer HP, Rucinski B, Isserow JA, Buchinsky FJ, Cvetkovic M, Liu CC, Epstein S. Related Articles, Links

Amylin increases bone volume but cannot ameliorate diabetic osteopenia.
Calcif Tissue Int. 1995 Jan;56(1):54-61.
PMID: 7796348 [PubMed - indexed for MEDLINE]

1: Diabet Med. 1997 Jun;14 Suppl 2:S9-13.

Related Articles, Links

Amylin: history and overview.

Ludvik B, Kautzky-Willer A, Prager R, Thomaseth K, Pacini G.

Klinik fur Innere Medizin III, Abteilung fur Endokrinologie und Stoffwechsel, University of Vienna, Austria.

The presence of amyloid deposits in the pancreas was first described at the beginning of the 20th century. However, it was not until 1987 that the structure of the amylin molecule was identified. Amylin is a 37-amino-acid peptide hormone that is co-secreted with insulin by the pancreatic beta-cells in response to a nutrient stimulus. It is deficient in patients with Type 1 diabetes and elevated in patients in the early stages of Type 2 diabetes, a condition which is characterized by hyperinsulinaemia. Elevation of plasma amylin levels has also been described in patients with impaired glucose tolerance, obese subjects and in pregnant women with both normal glucose tolerance and gestational diabetes mellitus. However, it appears that deficiencies of amylin secretion appear before those of insulin in patients in the later stages of Type 2 diabetes. Early experimental studies suggested that amylin inhibits basal insulin secretion, and induces insulin resistance in skeletal muscle, leading to the hypothesis that it has a role in the aetiology of Type 2 diabetes. However, a number of more recent experimental studies have indicated that amylin is a third active pancreatic islet hormone that works with insulin and glucagon to maintain glucose homeostasis. Amylin appears to regulate glucose inflow to the circulation by influencing the rate of gastric emptying, and thus the rate at which meal-derived glucose enters the system, and also by inhibiting glucose release and hepatic glucose production in the postprandial period.

Publication Types:
- Historical Article
- Review
- Review, Tutorial

PMID: 9212323 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

1: Peptides. 1997;18(4):537-40.

Related Articles, Links

Effects of amylin on human osteoblast-like cells.

Villa I, Rubinacci A, Ravasi F, Ferrara AF, Guidobono F.

Bone Metabolic Unit, Scientific Institute H San Raffaele, Milano, Italy.

Amylin has been reported to have bone-conserving effects. In the present study we evaluated the possible activity of the peptide on human osteoblast-like (hOB) cells in primary culture. Amylin between 10(-9) and 10(-6) M, dose-dependently stimulated cell proliferation with a maximal effect (200%) at 10(-6) M. In addition, amylin increased osteocalcin production when hOB cells were exposed to 1,25(OH)2D3 (10(-8)M) but there was a nonsignificant upward trend on alkaline phosphatase activity. The present results suggest that amylin could be included among the group of peptides endowed with osteogenic activity.

PMID: 9210172 [PubMed - indexed for MEDLINE]